

National Health (Pharmaceutical benefits—early supply) Instrument 2015

PB 120 of 2015

made under subsection 84AAA(2) of the

National Health Act 1953

**Compilation No.** **105**

**Compilation date:** 1 July 2025

**Includes amendments:** F2025L00776

**About this compilation**

**This compilation**

This is a compilation of the *National Health (Pharmaceutical benefits—early supply) Instrument 2015* that shows the text of the law as amended and in force on 1 July 2025 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

**Uncommenced amendments**

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Editorial changes**

For more information about any editorial changes made in this compilation, see the endnotes.

**Modifications**

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

**Self‑repealing provisions**

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

1 Name of Instrument 1

4 Definitions 1

5 Specification of pharmaceutical items 2

6 Circumstances relating to specification of pharmaceutical items in Schedule 1 2

7 Circumstances relating to specification of pharmaceutical items in Schedule 2 3

8 Specification of period relating to a pharmaceutical benefit 3

Schedule 1—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply 4

Schedule 2—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply– increased maximum quantity or number of units 73

Endnotes 125

Endnote 1—About the endnotes 125

Endnote 2—Abbreviation key 126

Endnote 3—Legislation history 127

Endnote 4—Amendment history 135

1 Name of Instrument

(1) This Instrument is the *National Health (Pharmaceutical benefits—early supply) Instrument 2015*.

(2) This Instrument may also be cited as PB 120 of 2015.

4 Definitions

(1) In this Instrument:

***Act*** means the *National Health Act 1953*.

***g*** means grams.

***I.U.*** means international unit.

***mg*** means milligram.

***mL*** means millilitre.

***pharmaceutical benefit*** has the meaning given by section 84 of the Act.

***pharmaceutical item*** has the meaning given by section 84AB of the Act.

***purposes code*** has the same meaning as in the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012.*

***relevant previous supply*** means the most recent previous supply to a person of:

(a) the same pharmaceutical benefit; or

(b) another pharmaceutical benefit that has the same pharmaceutical item as the pharmaceutical benefit; or

(c) another pharmaceutical benefit that is Schedule equivalent to the pharmaceutical benefit.

***relevant purpose***,for a pharmaceutical benefit, means a purpose, mentioned in Schedule 4 of the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012* for a purposes code specified in Schedule 1 of that instrument for the pharmaceutical benefit, that includes the phrase “The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient”.

***Schedule equivalent*** has the same meaning as in Part VII of the Act.

(2) A reference in this instrument to supply on the basis of a prescription includes reference to supply on the basis of a repeat authorisation or deferred supply authorisation.

5 Specification of pharmaceutical items

(1) A pharmaceutical item in a pharmaceutical benefit is specified for paragraph 84AAA(1)(a) of the Act if subsection (2) or (3) applies in relation to the pharmaceutical item.

(2) This subsection applies if:

(a) the listed drug and the form of that listed drug in the pharmaceutical item are mentioned in the table in Schedule 1; and

(b) all the circumstances identified in section 6 exist in relation to a benefit that has the listed drug and form in the table in Schedule 1.

(3) This subsection applies if:

(a) the listed drug and the form of that listed drug in the pharmaceutical item are mentioned in the table in Schedule 2; and

(b) all the circumstances identified in section 7 exist in relation to a pharmaceutical benefit that has the listed drug and form in the table in Schedule 2.

Note: All pharmaceutical items have a manner of administration determined under subsection 85(5) of the Act, so the listed drug in that form with that manner of administration is specified.

6 Circumstances relating to specification of pharmaceutical items in Schedule 1

(1) For paragraph 5(2)(b), the circumstances are as follows:

(a) the form mentioned in the table in Schedule 1 of a pharmaceutical benefit that has the listed drug is the same as the form determined under subsection 85(3) of the Act;

(b) a maximum quantity or number of units mentioned in the table in Schedule 1 for a benefit that has the listed drug and form is the same as a maximum quantity or number of units determined under paragraph 85A(2)(a) of the Act;

(c) a maximum number of repeats mentioned in the table in Schedule 1 for a benefit that has the listed drug and form is the same as a maximum number of repeats determined under paragraph 85A(2)(b) of the Act;

(d) where the supply of the pharmaceutical benefit was made on the basis of a prescription ̶ the quantity or number of units of the pharmaceutical benefit directed to be supplied on any one occasion in the prescription was not directed for a relevant purpose for the pharmaceutical benefit; and

(e) any other circumstance for paragraph 84AAA(3)(b) of the Act that is mentioned in the table in Schedule 1 for a benefit that has the listed drug and form.

7 Circumstances relating to specification of pharmaceutical items in Schedule 2

(1) For paragraph 5(3)(b), the circumstances are as follows:

(a) the form mentioned in the table in Schedule 2 of a pharmaceutical benefit that has the listed drug is the same as the form determined under subsection 85(3) of the Act;

(b) a maximum quantity or number of units mentioned in the table in Schedule 2 for a benefit that has the listed drug and form is the same as a maximum quantity or number of units determined under paragraph 85A(2)(a) of the Act;

(c) a maximum number of repeats mentioned in the table in Schedule 2 for a pharmaceutical benefit that has the listed drug and form is the same as a maximum number of repeats determined under paragraph 85A(2)(b) of the Act;

(d) the pharmaceutical benefit was supplied on the basis of a prescription;

(e) the quantity or number of units of the pharmaceutical benefit directed to be supplied on any one occasion in the prescription was directed for a relevant purpose for the pharmaceutical benefit; and

(f) any other circumstance for paragraph 84AAA(3)(b) of the Act that is mentioned in the table in Schedule 2 for a benefit that has the listed drug and form.

8 Specification of period relating to a pharmaceutical benefit

(1) This section is made for paragraph 84AAA(1)(b) of the Act.

(2) For a pharmaceutical benefit that has the listed drug and the form of the listed drug mentioned in the table in Schedule 1, and the circumstances identified for section 6 apply, the number mentioned under the heading ‘Period’ in the table in Schedule 1 for the listed drug and form is the period in days.

(3) For a pharmaceutical benefit that has the listed drug and the form of the listed drug mentioned in the table in Schedule 2, and the circumstances identified for section 7 apply:

(a) where the relevant previous supply to the person was on the basis of a prescription and the quantity or number of units of the pharmaceutical benefit directed to be supplied on any one occasion in the prescription was directed for a relevant purpose for the previously supplied pharmaceutical benefit – the number mentioned under the heading ‘Period’ for the listed drug and form is the period in days;

(b) in any other case – the period is 20 days.

Schedule 1—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply

| **Listed drug** | **Form** | **Period**  **(days)** | **Circumstances:** | | |
| --- | --- | --- | --- | --- | --- |
| **Maximum quantity or number of units** | **Maximum number of repeats** | **Other circumstances (if any)** |
| Abatacept | Injection 125 mg in 1 mL single dose autoinjector | 20 | 4 | 5 |  |
|  | Injection 125 mg in 1 mL single dose pre‑filled syringe | 20 | 4 | 5 |  |
| Abemaciclib | Tablet 50 mg | 20 | 56 | 5 |  |
|  | Tablet 100 mg | 20 | 56 | 5 |  |
|  | Tablet 150 mg | 20 | 56 | 5 |  |
| Abiraterone | Tablet containing abiraterone acetate 250 mg | 20 | 120 | 2 |  |
|  | Tablet containing abiraterone acetate 500 mg | 20 | 60 | 2 |  |
| Acalabrutinib | Tablet 100 mg | 20 | 56 | 5 |  |
|  |  | 20 | 56 | 6 |  |
| Aciclovir | Tablet 200 mg | 20 | 90 | 5 |  |
| Aclidinium | Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses | 20 | 1 | 5 |  |
| Aclidinium with formoterol | Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | 20 | 1 | 5 |  |
| Adalimumab | Injection 20 mg in 0.2 mL pre‑filled syringe | 20 | 2 | 0 |  |
|  |  | 20 | 2 | 3 |  |
|  |  | 20 | 2 | 5 |  |
|  |  | 20 | 2 | 6 |  |
|  | Injection 20 mg in 0.4 mL pre‑filled syringe | 20 | 2 | 0 |  |
|  |  | 20 | 2 | 3 |  |
|  |  | 20 | 2 | 5 |  |
|  |  | 20 | 2 | 6 |  |
|  | Injection 40 mg in 0.4 mL pre‑filled pen | 20 | 2 | 0 |  |
|  |  | 20 | 2 | 2 |  |
|  |  | 20 | 2 | 5 |  |
|  |  | 20 | 2 | 6 |  |
|  |  | 20 | 4 | 5 |  |
|  |  | 20 | 6 | 0 |  |
|  | Injection 40 mg in 0.4 mL pre‑filled syringe | 20 | 2 | 0 |  |
|  |  | 20 | 2 | 2 |  |
|  |  | 20 | 2 | 5 |  |
|  |  | 20 | 2 | 6 |  |
|  |  | 20 | 6 | 0 |  |
|  | Injection 40 mg in 0.8 mL pre‑filled pen | 20 | 2 | 0 |  |
|  |  | 20 | 2 | 2 |  |
|  |  | 20 | 2 | 5 |  |
|  |  | 20 | 2 | 6 |  |
|  |  | 20 | 4 | 5 |  |
|  |  | 20 | 6 | 0 |  |
|  | Injection 40 mg in 0.8 mL pre‑filled syringe | 20 | 2 | 0 |  |
|  |  | 20 | 2 | 2 |  |
|  |  | 20 | 2 | 5 |  |
|  |  | 20 | 2 | 6 |  |
|  |  | 20 | 6 | 0 |  |
|  | Injection 80 mg in 0.8 mL pre‑filled pen | 20 | 2 | 5 |  |
|  |  | 20 | 3 | 0 |  |
|  | Injection 80 mg in 0.8 mL pre‑filled syringe | 20 | 2 | 5 |  |
|  |  | 20 | 3 | 0 |  |
| Alendronic acid | Tablet 70 mg (as alendronate sodium) | 20 | 4 | 5 |  |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | 20 | 4 | 5 |  |
|  | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | 20 | 4 | 5 |  |
| Allopurinol | Tablet 100 mg | 20 | 200 | 2 |  |
|  | Tablet 300 mg | 20 | 60 | 2 |  |
| Alogliptin | Tablet 6.25 mg (as benzoate) | 20 | 28 | 5 |  |
|  | Tablet 12.5 mg (as benzoate) | 20 | 28 | 5 |  |
|  | Tablet 25 mg (as benzoate) | 20 | 28 | 5 |  |
| Alogliptin with metformin | Tablet containing 12.5 mg alogliptin (as benzoate) with 500 mg metformin hydrochloride | 20 | 56 | 5 |  |
|  | Tablet containing 12.5 mg alogliptin (as benzoate) with 850 mg metformin hydrochloride | 20 | 56 | 5 |  |
|  | Tablet containing 12.5 mg alogliptin (as benzoate) with 1 g metformin hydrochloride | 20 | 56 | 5 |  |
| Amantadine | Capsule containing amantadine hydrochloride 100 mg | 20 | 100 | 5 |  |
| Amifampridine | Tablet 10 mg | 20 | 200 | 5 |  |
| Amlodipine | Tablet 5 mg (as besilate) | 20 | 30 | 5 |  |
|  | Tablet 10 mg (as besilate) | 20 | 30 | 5 |  |
| Amlodipine with atorvastatin | Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | 20 | 30 | 5 |  |
| Amlodipine with valsartan | Tablet 5 mg (as besilate)‑80 mg | 20 | 28 | 5 |  |
|  | Tablet 5 mg (as besilate)‑160 mg | 20 | 28 | 5 |  |
|  | Tablet 5 mg (as besilate)‑320 mg | 20 | 28 | 5 |  |
|  | Tablet 10 mg (as besilate)‑160 mg | 20 | 28 | 5 |  |
|  | Tablet 10 mg (as besilate)‑320 mg | 20 | 28 | 5 |  |
| Amlodipine with valsartan and hydrochlorothiazide | Tablet 5 mg (as besilate)‑160 mg‑12.5 mg | 20 | 28 | 5 |  |
|  | Tablet 5 mg (as besilate)‑160 mg‑25 mg | 20 | 28 | 5 |  |
|  | Tablet 10 mg (as besilate)‑160 mg‑12.5 mg | 20 | 28 | 5 |  |
|  | Tablet 10 mg (as besilate)‑160 mg‑25 mg | 20 | 28 | 5 |  |
|  | Tablet 10 mg (as besilate)‑320 mg‑25 mg | 20 | 28 | 5 |  |
| Anastrozole | Tablet 1 mg | 20 | 30 | 5 |  |
| Apalutamide | Tablet 60 mg | 20 | 120 | 5 |  |
| Apixaban | Tablet 2.5 mg | 20 | 60 | 0 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 5 mg | 20 | 28 | 0 |  |
|  |  | 20 | 60 | 5 |  |
| Armodafinil | Tablet 50 mg | 20 | 60 | 5 |  |
|  | Tablet 150 mg | 20 | 30 | 5 |  |
|  | Tablet 250 mg | 20 | 30 | 5 |  |
| Asciminib | Tablet 20 mg | 20 | 60 | 5 |  |
|  | Tablet 40 mg | 20 | 60 | 5 |  |
|  |  | 20 | 300 | 5 |  |
| Aspirin | Tablet 100 mg | 20 | 112 | 1 |  |
| Atazanavir with cobicistat | Tablet containing 300 mg atazanavir and 150 mg cobicistat | 20 | 60 | 5 |  |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | 20 | 1 | 5 |  |
|  | Tablet 50 mg | 20 | 30 | 5 |  |
| Atomoxetine | Capsule 10 mg (as hydrochloride) | 20 | 56 | 5 |  |
|  | Capsule 18 mg (as hydrochloride) | 20 | 56 | 5 |  |
|  | Capsule 25 mg (as hydrochloride) | 20 | 56 | 5 |  |
|  | Capsule 40 mg (as hydrochloride) | 20 | 56 | 5 |  |
|  | Capsule 60 mg (as hydrochloride) | 20 | 56 | 5 |  |
|  | Capsule 80 mg (as hydrochloride) | 20 | 28 | 5 |  |
|  | Capsule 100 mg (as hydrochloride) | 20 | 28 | 5 |  |
| Atorvastatin | Tablet 10 mg (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 20 mg (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 40 mg (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 80 mg (as calcium) | 20 | 30 | 5 |  |
| Auranofin | Capsule 3 mg | 20 | 60 | 5 |  |
|  | Tablet 3 mg | 20 | 60 | 5 |  |
| Azacitidine | Tablet 200 mg | 20 | 14 | 2 |  |
|  | Tablet 300 mg | 20 | 14 | 2 |  |
|  |  | 20 | 21 | 1 |  |
| Azathioprine | Tablet 25 mg | 20 | 100 | 5 |  |
|  | Tablet 50 mg | 20 | 100 | 5 |  |
| Baclofen | Tablet 10 mg | 20 | 100 | 5 |  |
|  | Tablet 25 mg | 20 | 100 | 5 |  |
| Balsalazide | Capsule containing balsalazide sodium 750 mg | 20 | 280 | 5 |  |
| Baricitinib | Tablet 2 mg | 20 | 28 | 5 |  |
|  | Tablet 4 mg | 20 | 28 | 5 |  |
| Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses | 20 | 1 | 5 |  |
|  | Pressurised inhalation containing beclometasone dipropionate 200 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses | 20 | 1 | 5 |  |
| Betaine | Oral powder 180 g | 20 | 1 | 5 |  |
| Betamethasone | Injection containing betamethasone acetate 3 mg with betamethasone sodium phosphate 3.9 mg in 1 mL | 20 | 5 | 0 |  |
| Bicalutamide | Tablet 50 mg | 20 | 28 | 5 |  |
| Bictegravir with emtricitabine with tenofovir alafenamide | Tablet containing bictegravir 50 mg with emtricitabine 200 mg with tenofovir alafenamide 25 mg | 20 | 60 | 5 |  |
| Bimekizumab | Injection 160 mg in 1 mL single use pre‑filled pen | 20 | 2 | 1 |  |
|  |  | 20 | 2 | 2 |  |
|  |  | 20 | 2 | 4 |  |
| Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | 20 | 28 | 5 |  |
|  | Tablet containing bisoprolol fumarate 5 mg | 20 | 28 | 5 |  |
|  | Tablet containing bisoprolol fumarate 10 mg | 20 | 28 | 5 |  |
| Brexpiprazole | Tablet 1 mg | 20 | 30 | 0 |  |
|  | Tablet 2 mg | 20 | 30 | 5 |  |
|  | Tablet 3 mg | 20 | 30 | 5 |  |
|  | Tablet 4 mg | 20 | 30 | 5 |  |
| Brivaracetam | Oral solution 10 mg per mL, 300 mL | 20 | 1 | 5 |  |
|  | Tablet 25 mg | 20 | 56 | 5 |  |
|  | Tablet 50 mg | 20 | 56 | 5 |  |
|  | Tablet 75 mg | 20 | 56 | 5 |  |
|  | Tablet 100 mg | 20 | 56 | 5 |  |
| Budesonide with glycopyrronium and formoterol | Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | 20 | 1 | 5 |  |
| Buprenorphine | Injection (modified release) 8 mg in 0.16 mL pre‑filled syringe | 20 | 4 | 5 |  |
|  | Injection (modified release) 16 mg in 0.32 mL pre‑filled syringe | 20 | 4 | 5 |  |
|  | Injection (modified release) 24 mg in 0.48 mL pre‑filled syringe | 20 | 4 | 5 |  |
|  | Injection (modified release) 32 mg in 0.64 mL pre‑filled syringe | 20 | 4 | 5 |  |
|  | Injection (modified release) 64 mg in 0.18 mL pre‑filled syringe | 20 | 1 | 5 |  |
|  | Injection (modified release) 96 mg in 0.27 mL pre‑filled syringe | 20 | 1 | 5 |  |
|  | Injection (modified release) 100 mg in 0.5 mL pre‑filled syringe | 20 | 1 | 5 |  |
|  | Injection (modified release) 128 mg in 0.36 mL pre‑filled syringe | 20 | 1 | 5 |  |
|  | Injection (modified release) 160 mg in 0.45 mL pre‑filled syringe | 20 | 1 | 5 |  |
|  | Injection (modified release) 300 mg in 1.5 mL pre‑filled syringe | 20 | 1 | 5 |  |
|  | Tablet (sublingual) 400 micrograms (as hydrochloride) | 20 | 28 | 5 |  |
|  | Tablet (sublingual) 2 mg (as hydrochloride) | 20 | 84 | 5 |  |
|  | Tablet (sublingual) 8 mg (as hydrochloride) | 20 | 112 | 5 |  |
| Buprenorphine with naloxone | Film (soluble) 2 mg (as hydrochloride)‑0.5 mg (as hydrochloride) | 20 | 84 | 5 |  |
|  | Film (soluble) 8 mg (as hydrochloride)‑2 mg (as hydrochloride) | 20 | 112 | 5 |  |
| Bupropion | Tablet containing bupropion hydrochloride 150 mg (sustained release) | 20 | 30 | 0 |  |
|  |  | 20 | 90 | 0 |  |
| Cabergoline | Tablet 1 mg | 20 | 30 | 5 |  |
|  | Tablet 2 mg | 20 | 30 | 5 |  |
| Cabozantinib | Tablet 20 mg | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 5 |  |
|  | Tablet 40 mg | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 5 |  |
|  | Tablet 60 mg | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 5 |  |
| Calcitonin salmon | Injection 100 I.U. in 1 mL | 20 | 15 | 5 |  |
| Calcitriol | Capsule 0.25 microgram | 20 | 100 | 3 |  |
| Calcium | Tablet 600 mg (as carbonate) | 20 | 240 | 1 |  |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | 20 | 30 | 5 |  |
|  | Tablet containing candesartan cilexetil 8 mg | 20 | 30 | 5 |  |
|  | Tablet containing candesartan cilexetil 16 mg | 20 | 30 | 5 |  |
|  | Tablet containing candesartan cilexetil 32 mg | 20 | 30 | 5 |  |
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | 20 | 30 | 5 |  |
| Carbamazepine | Tablet 100 mg | 20 | 200 | 0 |  |
|  |  | 20 | 200 | 2 |  |
|  | Tablet 200 mg | 20 | 200 | 0 |  |
|  |  | 20 | 200 | 2 |  |
|  | Tablet 200 mg (controlled release) | 20 | 200 | 0 |  |
|  |  | 20 | 200 | 2 |  |
|  | Tablet 400 mg (controlled release) | 20 | 200 | 0 |  |
|  |  | 20 | 200 | 2 |  |
| Carvedilol | Tablet 6.25 mg | 20 | 60 | 5 |  |
|  | Tablet 12.5 mg | 20 | 60 | 5 |  |
|  | Tablet 25 mg | 20 | 60 | 5 |  |
| Certolizumab pegol | Injection 200 mg in 1 mL single use pre‑filled syringe | 20 | 2 | 5 |  |
|  | Solution for injection 200 mg in 1 mL pre‑filled pen | 20 | 2 | 5 |  |
| Citalopram | Tablet 20 mg (as hydrobromide) | 20 | 28 | 5 |  |
|  | Tablet 40 mg (as hydrobromide) | 20 | 28 | 5 |  |
| Clonazepam | Tablet 2 mg | 20 | 200 | 2 |  |
|  | Tablet 500 micrograms | 20 | 200 | 2 |  |
| Clonidine | Tablet containing clonidine hydrochloride 100 micrograms | 20 | 100 | 5 |  |
|  | Tablet containing clonidine hydrochloride 150 micrograms | 20 | 100 | 5 |  |
| Clopidogrel | Tablet 75 mg (as besilate) | 20 | 28 | 5 |  |
|  | Tablet 75 mg (as hydrogen sulfate) | 20 | 28 | 5 |  |
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)‑100 mg | 20 | 30 | 5 |  |
| Dabigatran etexilate | Capsule 75 mg (as mesilate) | 20 | 60 | 0 |  |
|  | Capsule 110 mg (as mesilate) | 20 | 60 | 0 |  |
|  |  | 20 | 60 | 5 |  |
|  | Capsule 150 mg (as mesilate) | 20 | 60 | 5 |  |
| Dapagliflozin | Tablet 10 mg (as propanediol monohydrate) | 20 | 28 | 5 |  |
| Dapagliflozin with metformin | Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride | 20 | 56 | 5 |  |
|  | Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride | 20 | 28 | 5 |  |
|  | Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride | 20 | 28 | 5 |  |
| Dapagliflozin with sitagliptin | Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 100 mg sitagliptin (as phosphate monohydrate) | 20 | 28 | 5 |  |
| Dapsone | Tablet 25 mg | 20 | 100 | 1 |  |
|  | Tablet 100 mg | 20 | 100 | 1 |  |
| Darolutamide | Tablet 300 mg | 20 | 112 | 5 |  |
| Darunavir with cobicistat, emtricitabine and tenofovir alafenamide | Tablet containing darunavir 800 mg with cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg | 20 | 60 | 5 |  |
| Dasatinib | Tablet 20 mg | 20 | 60 | 2 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 50 mg | 20 | 60 | 2 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 70 mg | 20 | 60 | 2 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 100 mg | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 5 |  |
| Decitabine with cedazuridine | Tablet containing decitabine 35 mg with cedazuridine 100 mg | 20 | 5 | 2 |  |
|  |  | 20 | 5 | 5 |  |
| Degarelix | Powder for injection 80 mg (as acetate), injection set | 20 | 1 | 5 |  |
|  | Powder for injection 120 mg (as acetate), 2, injection set | 20 | 1 | 0 |  |
| Denosumab | Injection 60 mg in 1 mL pre‑filled syringe | 20 | 1 | 0 |  |
| Desmopressin | Tablet containing desmopressin acetate 200 micrograms | 20 | 30 | 5 |  |
|  |  | 20 | 90 | 5 |  |
|  | Wafer 120 micrograms (as acetate) | 20 | 30 | 5 |  |
|  | Wafer 240 micrograms (as acetate) | 20 | 30 | 5 |  |
| Desvenlafaxine | Tablet (extended release) 50 mg (as succinate) | 20 | 28 | 5 |  |
|  | Tablet (extended release) 100 mg (as succinate) | 20 | 28 | 5 |  |
|  | Tablet (modified release) 50 mg | 20 | 28 | 5 |  |
|  | Tablet (modified release) 50 mg (as benzoate) | 20 | 28 | 5 |  |
|  | Tablet (modified release) 100 mg | 20 | 28 | 5 |  |
|  | Tablet (modified release) 100 mg (as benzoate) | 20 | 28 | 5 |  |
| Deucravacitinib | Tablet 6 mg | 20 | 28 | 5 |  |
| Dienogest | Tablet 2 mg | 20 | 28 | 5 |  |
| Digoxin | Tablet 62.5 micrograms | 20 | 200 | 1 |  |
|  | Tablet 250 micrograms | 20 | 100 | 1 |  |
| Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | 20 | 30 | 5 |  |
|  | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | 20 | 30 | 5 |  |
|  | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | 20 | 30 | 5 |  |
|  | Tablet containing diltiazem hydrochloride 60 mg | 20 | 90 | 5 |  |
| Dimethyl fumarate | Capsule (modified release) 240 mg | 20 | 56 | 5 |  |
| Diroximel fumarate | Capsule (enteric) 231 mg | 20 | 120 | 5 |  |
| Dolutegravir with lamivudine | Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg | 20 | 60 | 5 |  |
| Dolutegravir with rilpivirine | Tablet containing dolutegravir 50 mg (as sodium) with rilpivirine 25 mg (as hydrochloride) | 20 | 60 | 5 |  |
| Donepezil | Tablet containing donepezil hydrochloride 5 mg | 20 | 28 | 5 |  |
|  | Tablet containing donepezil hydrochloride 10 mg | 20 | 28 | 5 |  |
| Drospirenone | Pack containing 24 tablets 4 mg and 4 inert tablets | 20 | 4 | 2 |  |
| Drospirenone with ethinylestradiol | Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets | 20 | 3 | 3 |  |
|  | Pack containing 24 tablets 3 mg drospirenone with 20 micrograms ethinylestradiol (as betadex clathrate) and 4 inert tablets | 20 | 3 | 3 |  |
| Dulaglutide | Injection 1.5 mg in 0.5 mL single dose pre‑filled pen | 20 | 4 | 5 |  |
| Duloxetine | Capsule 60 mg (as hydrochloride) | 20 | 28 | 5 |  |
| Dupilumab | Injection 200 mg in 1.14 mL single dose pre‑filled syringe | 20 | 2 | 5 |  |
|  | Injection 300 mg in 2 mL single dose pre‑filled syringe | 20 | 2 | 5 |  |
| Dutasteride | Capsule 500 micrograms | 20 | 30 | 5 |  |
| Dutasteride with tamsulosin | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms | 20 | 30 | 5 |  |
| Empagliflozin | Tablet 10 mg | 20 | 30 | 5 |  |
|  | Tablet 25 mg | 20 | 30 | 5 |  |
| Empagliflozin with linagliptin | Tablet containing 10 mg empagliflozin with 5 mg linagliptin | 20 | 30 | 5 |  |
|  | Tablet containing 25 mg empagliflozin with 5 mg linagliptin | 20 | 30 | 5 |  |
| Empagliflozin with metformin | Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride | 20 | 60 | 5 |  |
|  | Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride | 20 | 60 | 5 |  |
|  | Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride | 20 | 60 | 5 |  |
|  | Tablet containing 12.5 mg empagliflozin with 1 g metformin hydrochloride | 20 | 60 | 5 |  |
| Enalapril | Tablet containing enalapril maleate 5 mg | 20 | 30 | 5 |  |
|  | Tablet containing enalapril maleate 10 mg | 20 | 30 | 5 |  |
|  | Tablet containing enalapril maleate 20 mg | 20 | 30 | 5 |  |
| Enalapril with hydrochlorothiazide | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | 20 | 30 | 5 |  |
| Entacapone | Tablet 200 mg | 20 | 200 | 4 |  |
| Enzalutamide | Capsule 40 mg | 20 | 112 | 2 |  |
|  |  | 20 | 112 | 5 |  |
| Eplerenone | Tablet 25 mg | 20 | 30 | 5 |  |
|  | Tablet 50 mg | 20 | 30 | 5 |  |
| Eprosartan | Tablet 600 mg (as mesilate) | 20 | 28 | 5 |  |
| Eprosartan with hydrochlorothiazide | Tablet 600 mg eprosartan (as mesilate) with 12.5 mg hydrochlorothiazide | 20 | 28 | 5 |  |
| Erlotinib | Tablet 25 mg (as hydrochloride) | 20 | 30 | 3 |  |
|  | Tablet 100 mg (as hydrochloride) | 20 | 30 | 3 |  |
|  | Tablet 150 mg (as hydrochloride) | 20 | 30 | 3 |  |
| Escitalopram | Tablet 10 mg (as oxalate) | 20 | 28 | 5 |  |
|  | Tablet 20 mg (as oxalate) | 20 | 28 | 5 |  |
| Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Capsule (enteric) 40 mg (as magnesium) | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet (enteric coated) 20 mg (as magnesium) | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet (enteric coated) 40 mg (as magnesium) | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
| Esomeprazole and clarithromycin and amoxicillin | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) | 20 | 1 | 0 |  |
|  | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) | 20 | 1 | 0 |  |
| Estradiol | Tablet 2 mg | 20 | 56 | 2 |  |
|  | Tablet containing estradiol valerate 1 mg | 20 | 56 | 2 |  |
|  | Tablet containing estradiol valerate 2 mg | 20 | 56 | 2 |  |
|  | Transdermal gel (pump pack) 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses | 20 | 1 | 5 |  |
|  | Transdermal gel 500 micrograms in 0.5 g sachet, 28 | 20 | 1 | 5 |  |
|  | Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28 | 20 | 1 | 5 |  |
|  | Transdermal patches 390 micrograms, 8 | 20 | 1 | 5 |  |
|  | Transdermal patches 390 micrograms, 24 (S19A) | 20 | 1 | 1 |  |
|  | Transdermal patches 585 micrograms, 8 | 20 | 1 | 5 |  |
|  | Transdermal patches 750 micrograms (as hemihydrate), 8 | 20 | 1 | 5 |  |
|  | Transdermal patches 780 micrograms, 8 | 20 | 1 | 5 |  |
|  | Transdermal patches 780 micrograms, 24 (S19A) | 20 | 1 | 1 |  |
|  | Transdermal patches 1.17 mg, 8 | 20 | 1 | 5 |  |
|  | Transdermal patches 1.17 mg, 24 (S19A) | 20 | 1 | 1 |  |
|  | Transdermal patches 1.5 mg (as hemihydrate), 8 | 20 | 1 | 5 |  |
|  | Transdermal patches 1.56 mg, 8 | 20 | 1 | 5 |  |
|  | Transdermal patches 1.56 mg, 24 (Sandoz) (S19A) | 20 | 1 | 1 |  |
|  | Transdermal patches 3 mg (as hemihydrate), 8 | 20 | 1 | 5 |  |
| Estradiol and estradiol with dydrogesterone | Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg | 20 | 1 | 5 |  |
|  | Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg | 20 | 1 | 5 |  |
| Estradiol and estradiol with norethisterone | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate | 20 | 1 | 5 |  |
|  | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate | 20 | 1 | 5 |  |
| Estradiol with norethisterone | Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 | 20 | 1 | 5 |  |
|  | Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A) | 20 | 1 | 5 |  |
|  | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 | 20 | 1 | 5 |  |
|  | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A) | 20 | 1 | 5 |  |
| Etanercept | Injection 50 mg in 1 mL single use auto‑injector, 4 | 20 | 1 | 3 |  |
|  |  | 20 | 1 | 5 |  |
|  | Injection set containing 4 vials powder for injection 25 mg and 4 pre‑filled syringes solvent 1 mL | 20 | 2 | 3 |  |
|  |  | 20 | 2 | 5 |  |
|  | Injections 50 mg in 1 mL single use pre‑filled syringes, 4 | 20 | 1 | 3 |  |
|  |  | 20 | 1 | 5 |  |
| Ethosuximide | Capsule 250 mg | 20 | 200 | 2 |  |
|  | Capsule 250 mg (s19A) | 20 | 200 | 2 |  |
| Etonogestrel | Subcutaneous implant 68 mg | 20 | 1 | 0 |  |
| Etrasimod | Tablet 2 mg | 20 | 28 | 3 |  |
|  |  | 20 | 28 | 5 |  |
| Evolocumab | Injection 140 mg in 1 mL single use pre‑filled pen | 20 | 2 | 5 |  |
|  |  | 20 | 3 | 5 |  |
| Ezetimibe | Tablet 10 mg | 20 | 30 | 5 |  |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | 20 | 1 | 5 |  |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | 20 | 1 | 5 |  |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | 20 | 1 | 5 |  |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | 20 | 1 | 5 |  |
| Ezetimibe with atorvastatin | Tablet 10 mg‑10 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg‑20 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg‑40 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg‑80 mg | 20 | 30 | 5 |  |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg‑20 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg‑40 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg‑80 mg | 20 | 30 | 5 |  |
| Famciclovir | Tablet 250 mg | 20 | 56 | 5 |  |
|  | Tablet 500 mg | 20 | 56 | 5 |  |
| Famotidine | Tablet 20 mg | 20 | 60 | 5 |  |
|  | Tablet 40 mg | 20 | 30 | 5 |  |
| Febuxostat | Tablet 80 mg | 20 | 28 | 5 |  |
| Felodipine | Tablet 2.5 mg (extended release) | 20 | 30 | 5 |  |
|  | Tablet 5 mg (extended release) | 20 | 30 | 5 |  |
|  | Tablet 10 mg (extended release) | 20 | 30 | 5 |  |
| Fenofibrate | Tablet 48 mg | 20 | 60 | 5 |  |
|  | Tablet 145 mg | 20 | 30 | 5 |  |
| Fingolimod | Capsule 250 micrograms (as hydrochloride) | 20 | 28 | 5 |  |
|  | Capsule 500 micrograms (as hydrochloride) | 20 | 28 | 5 |  |
| Fludarabine | Tablet containing fludarabine phosphate 10 mg | 20 | 20 | 5 |  |
| Fludrocortisone | Tablet containing fludrocortisone acetate 100 micrograms | 20 | 200 | 1 |  |
| Flutamide | Tablet 250 mg | 20 | 100 | 5 |  |
| Fluticasone furoate | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses | 20 | 1 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses | 20 | 1 | 5 |  |
| Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | 20 | 1 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | 20 | 1 | 5 |  |
| Fluvastatin | Tablet (prolonged release) 80 mg (as sodium) | 20 | 28 | 5 |  |
| Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | 20 | 30 | 5 |  |
|  | Tablet containing fluvoxamine maleate 100 mg | 20 | 30 | 5 |  |
| Folic acid | Tablet 500 micrograms | 20 | 200 | 0 |  |
|  | Tablet 5 mg | 20 | 200 | 1 |  |
| Fosinopril | Tablet containing fosinopril sodium 10 mg | 20 | 30 | 5 |  |
|  | Tablet containing fosinopril sodium 20 mg | 20 | 30 | 5 |  |
| Fremanezumab | Solution for injection 225 mg in 1.5 mL single dose pre‑filled pen | 20 | 1 | 2 |  |
|  |  | 20 | 1 | 5 |  |
|  | Solution for injection 225 mg in 1.5 mL single dose pre‑filled syringe | 20 | 1 | 2 |  |
|  |  | 20 | 1 | 5 |  |
| Furosemide | Tablet 20 mg | 20 | 100 | 1 |  |
|  | Tablet 40 mg | 20 | 100 | 1 |  |
| Gabapentin | Capsule 100 mg | 20 | 100 | 5 |  |
|  | Capsule 300 mg | 20 | 100 | 5 |  |
|  | Capsule 400 mg | 20 | 100 | 5 |  |
|  | Tablet 600 mg | 20 | 100 | 5 |  |
|  | Tablet 800 mg | 20 | 100 | 5 |  |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | 20 | 28 | 5 |  |
|  | Capsule (prolonged release) 16 mg (as hydrobromide) | 20 | 28 | 5 |  |
|  | Capsule (prolonged release) 24 mg (as hydrobromide) | 20 | 28 | 5 |  |
| Galcanezumab | Injection 120 mg in 1 mL pre‑filled pen | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 1 |  |
| Gemfibrozil | Tablet 600 mg | 20 | 60 | 5 |  |
| Gliclazide | Tablet 60 mg (modified release) | 20 | 60 | 5 |  |
|  | Tablet 80 mg | 20 | 100 | 5 |  |
| Glimepiride | Tablet 3 mg | 20 | 30 | 5 |  |
|  | Tablet 4 mg | 20 | 30 | 5 |  |
| Glyceryl trinitrate | Transdermal patch 18 mg | 20 | 30 | 5 |  |
|  | Transdermal patch 25 mg | 20 | 30 | 5 |  |
|  | Transdermal patch 36 mg | 20 | 30 | 5 |  |
|  | Transdermal patch 50 mg | 20 | 30 | 5 |  |
|  | Transdermal patch 54 mg | 20 | 30 | 5 |  |
| Glycopyrronium | Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler) | 20 | 30 | 5 |  |
| Golimumab | Injection 50 mg in 0.5 mL single use pre‑filled pen | 20 | 1 | 5 |  |
|  | Injection 50 mg in 0.5 mL single use pre‑filled syringe | 20 | 1 | 5 |  |
|  | Injection 100 mg in 1 mL single use pre‑filled pen | 20 | 1 | 5 |  |
| Goserelin | Subcutaneous implant 3.6 mg (as acetate) in pre‑filled injection syringe | 20 | 1 | 5 |  |
|  | Subcutaneous implant (long acting) 10.8 mg (as acetate) in pre‑filled injection syringe | 20 | 1 | 1 |  |
| Goserelin and bicalutamide | Pack containing 1 subcutaneous implant containing goserelin 3.6 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg | 20 | 1 | 5 |  |
|  | Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg | 20 | 1 | 0 |  |
|  | Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 84 tablets bicalutamide 50 mg | 20 | 1 | 1 |  |
| Griseofulvin | Tablet 125 mg | 20 | 100 | 2 |  |
| Guanfacine | Tablet 1 mg (as hydrochloride) | 20 | 28 | 5 |  |
|  | Tablet 2 mg (as hydrochloride) | 20 | 28 | 5 |  |
|  | Tablet 3 mg (as hydrochloride) | 20 | 28 | 5 |  |
|  | Tablet 4 mg (as hydrochloride) | 20 | 28 | 5 |  |
| Hydrochlorothiazide | Tablet 25 mg | 20 | 100 | 1 |  |
| Hydrochlorothiazide with amiloride | Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg | 20 | 100 | 1 |  |
| Hydroxocobalamin | Injection 1 mg (as acetate) in 1 mL | 20 | 3 | 0 |  |
|  | Injection 1 mg (as chloride) in 1 mL | 20 | 3 | 0 |  |
| Hydroxychloroquine | Tablet containing hydroxychloroquine sulfate 200 mg | 20 | 100 | 1 |  |
| Ibandronic acid | Tablet 50 mg (as ibandronate sodium monohydrate) | 20 | 28 | 2 |  |
| Ibrutinib | Capsule 140 mg | 20 | 90 | 2 |  |
|  |  | 20 | 90 | 4 |  |
|  |  | 20 | 90 | 5 |  |
|  |  | 20 | 120 | 5 |  |
|  | Tablet 280 mg | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 4 |  |
|  |  | 20 | 30 | 5 |  |
|  | Tablet 420 mg | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 4 |  |
|  |  | 20 | 30 | 5 |  |
|  | Tablet 560 mg | 20 | 30 | 5 |  |
| Icosapent ethyl | Capsule 998 mg | 20 | 120 | 5 |  |
| Idelalisib | Tablet 100 mg | 20 | 60 | 5 |  |
|  | Tablet 150 mg | 20 | 60 | 5 |  |
| Imatinib | Capsule 100 mg (as mesilate) | 20 | 60 | 2 |  |
|  |  | 20 | 60 | 5 |  |
|  | Capsule 400 mg (as mesilate) | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 5 |  |
|  | Tablet 100 mg (as mesilate) | 20 | 60 | 2 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 400 mg (as mesilate) | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 5 |  |
|  | Tablet 600 mg (as mesilate) | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 5 |  |
| Indacaterol | Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler) | 20 | 30 | 5 |  |
|  | Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler) | 20 | 30 | 5 |  |
| Indacaterol with glycopyrronium | Capsule containing powder for oral inhalation indacaterol 110 micrograms (as maleate) with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler) | 20 | 30 | 5 |  |
| Indacaterol with glycopyrronium and mometasone | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 136 micrograms (for use in Breezhaler) | 20 | 30 | 5 |  |
|  | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 68 micrograms (for use in Breezhaler) | 20 | 30 | 5 |  |
| Indapamide | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | 20 | 90 | 1 |  |
|  | Tablet containing indapamide hemihydrate 2.5 mg | 20 | 90 | 1 |  |
| Infliximab | Solution for injection 120 mg in 1 mL pre‑filled pen | 20 | 1 | 0 |  |
|  |  | 20 | 2 | 0 |  |
|  |  | 20 | 2 | 2 |  |
|  |  | 20 | 2 | 5 |  |
|  | Solution for injection 120 mg in 1 mL pre‑filled syringe | 20 | 1 | 0 |  |
|  |  | 20 | 2 | 0 |  |
|  |  | 20 | 2 | 2 |  |
|  |  | 20 | 2 | 5 |  |
| Insulin aspart | Injection (human analogue) 100 units per mL, 10 mL vial | 20 | 5 | 2 |  |
|  | Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
|  | Injections (human analogue) (fast acting), cartridges, 100 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
| Insulin aspart with insulin aspart protamine suspension | Injections (human analogue), cartridges, 30 units‑70 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
| Insulin detemir | Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
| Insulin glulisine | Injection (human analogue) 100 units per mL, 10 mL | 20 | 5 | 2 |  |
|  | Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
| Insulin isophane | Injection (human) 100 units per mL, 10 mL | 20 | 5 | 2 |  |
|  | Injections (human), cartridges, 100 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
| Insulin lispro | Injection (human analogue) 100 units per mL, 10 mL vial | 20 | 5 | 2 |  |
|  | Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
|  | Injections (human analogue), pre‑filled pen, 200 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
| Insulin lispro with insulin lispro protamine suspension | Injections (human analogue), cartridges, 25 units‑75 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
|  | Injections (human analogue), cartridges, 50 units‑50 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
| Insulin neutral | Injection (human) 100 units per mL, 10 mL | 20 | 5 | 2 |  |
|  | Injections (human), cartridges, 100 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
| Insulin neutral with insulin isophane | Injection (human) 30 units‑70 units per mL, 10 mL | 20 | 5 | 2 |  |
|  | Injections (human), cartridges, 30 units‑70 units per mL, 3 mL, 5 | 20 | 5 | 1 |  |
| Irbesartan | Tablet 75 mg | 20 | 30 | 5 |  |
|  | Tablet 150 mg | 20 | 30 | 5 |  |
|  | Tablet 300 mg | 20 | 30 | 5 |  |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg‑12.5 mg | 20 | 30 | 5 |  |
|  | Tablet 300 mg‑12.5 mg | 20 | 30 | 5 |  |
|  | Tablet 300 mg‑25 mg | 20 | 30 | 5 |  |
| Isosorbide mononitrate | Tablet 60 mg (sustained release) | 20 | 30 | 5 |  |
|  | Tablet 120 mg (sustained release) | 20 | 30 | 5 |  |
| Ivabradine | Tablet 5 mg (as hydrochloride) | 20 | 56 | 5 |  |
|  | Tablet 7.5 mg (as hydrochloride) | 20 | 56 | 5 |  |
| Ivosidenib | Tablet 250 mg | 20 | 60 | 5 |  |
| Ixekizumab | Injection 80 mg in 1 mL single dose pre‑filled pen | 20 | 2 | 2 |  |
| Ketoprofen | Capsule 200 mg (sustained release) | 20 | 28 | 0 |  |
|  |  | 20 | 28 | 3 |  |
| Labetalol | Tablet containing labetalol hydrochloride 100 mg | 20 | 100 | 5 |  |
| Lacosamide | Tablet 100 mg | 20 | 56 | 5 |  |
|  | Tablet 150 mg | 20 | 56 | 5 |  |
|  | Tablet 200 mg | 20 | 56 | 5 |  |
| Lamotrigine | Tablet 5 mg | 20 | 56 | 5 |  |
|  | Tablet 25 mg | 20 | 56 | 5 |  |
|  | Tablet 50 mg | 20 | 56 | 5 |  |
|  | Tablet 100 mg | 20 | 56 | 5 |  |
|  | Tablet 200 mg | 20 | 56 | 5 |  |
| Lanadelumab | Injection 300 mg in 2 mL single use pre‑filled syringe | 20 | 1 | 5 |  |
| Lansoprazole | Capsule 15 mg | 20 | 30 | 5 |  |
|  | Capsule 30 mg | 20 | 28 | 1 |  |
|  |  | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 15 mg (orally disintegrating) | 20 | 28 | 5 |  |
|  | Tablet 30 mg (orally disintegrating) | 20 | 28 | 1 |  |
|  |  | 20 | 28 | 5 |  |
|  |  | 20 | 56 | 5 |  |
| Leflunomide | Tablet 10 mg | 20 | 30 | 5 |  |
|  | Tablet 20 mg | 20 | 30 | 5 |  |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | 20 | 28 | 5 |  |
|  | Tablet containing lercanidipine hydrochloride 20 mg | 20 | 28 | 5 |  |
| Lercanidipine with enalapril | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg | 20 | 28 | 5 |  |
|  | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg | 20 | 28 | 5 |  |
| Letrozole | Tablet 2.5 mg | 20 | 30 | 5 |  |
| Leuprorelin | I.M. injection (3 month modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre‑filled dual‑chamber syringe | 20 | 1 | 1 |  |
|  | I.M. injection (modified release), powder for injection containing leuprorelin acetate 7.5 mg with diluent in pre‑filled dual‑chamber syringe | 20 | 1 | 5 |  |
|  | I.M. injection (modified release), powder for injection containing leuprorelin acetate 22.5 mg with diluent in pre‑filled dual‑chamber syringe | 20 | 1 | 1 |  |
|  | I.M. injection (modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre‑filled dual‑chamber syringe | 20 | 1 | 1 |  |
|  | I.M. injection (modified release), powder for injection containing leuprorelin acetate 45 mg with diluent in pre‑filled dual‑chamber syringe | 20 | 1 | 0 |  |
|  | Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 7.5 mg, injection set | 20 | 1 | 5 |  |
|  | Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 22.5 mg, injection set | 20 | 1 | 1 |  |
|  | Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 30 mg, injection set | 20 | 1 | 1 |  |
|  | Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 45 mg, injection set | 20 | 1 | 0 |  |
| Leuprorelin and bicalutamide | Pack containing 1 syringe containing leuprorelin 7.5 mg (as acetate) and 28 tablets bicalutamide 50 mg | 20 | 1 | 5 |  |
|  | Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 28 tablets bicalutamide 50 mg | 20 | 1 | 0 |  |
|  | Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 84 tablets bicalutamide 50 mg | 20 | 1 | 1 |  |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL | 20 | 1 | 5 |  |
|  | Tablet 250 mg | 20 | 60 | 5 |  |
|  | Tablet 500 mg | 20 | 60 | 5 |  |
|  | Tablet 1 g | 20 | 60 | 5 |  |
| Levodopa with carbidopa and entacapone | Tablet 50 mg‑12.5 mg (as monohydrate)‑200 mg | 20 | 200 | 4 |  |
|  | Tablet 75 mg‑18.75 mg (as monohydrate)‑200 mg | 20 | 200 | 4 |  |
|  | Tablet 100 mg‑25 mg (as monohydrate)‑200 mg | 20 | 200 | 4 |  |
|  | Tablet 125 mg‑31.25 mg (as monohydrate)‑200 mg | 20 | 200 | 4 |  |
|  | Tablet 150 mg‑37.5 mg (as monohydrate)‑200 mg | 20 | 200 | 4 |  |
|  | Tablet 200 mg‑50 mg (as monohydrate)‑200 mg | 20 | 200 | 4 |  |
| Levonorgestrel | Intrauterine drug delivery system 19.5 mg | 20 | 1 | 0 |  |
|  | Intrauterine drug delivery system 52 mg | 20 | 1 | 0 |  |
|  | Tablets 30 micrograms, 28 | 20 | 4 | 2 |  |
| Levonorgestrel with ethinylestradiol | Pack containing 6 tablets 50 micrograms‑30 micrograms, 5 tablets 75 micrograms‑40 micrograms, 10 tablets 125 micrograms‑30 micrograms and 7 inert tablets | 20 | 4 | 2 |  |
|  | Pack containing 21 tablets 100 micrograms‑20 micrograms and 7 inert tablets | 20 | 4 | 2 |  |
|  | Pack containing 21 tablets 125 micrograms‑50 micrograms and 7 inert tablets | 20 | 4 | 2 |  |
|  | Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | 20 | 4 | 2 |  |
| Levothyroxine | Tablet containing 50 micrograms anhydrous levothyroxine sodium | 20 | 200 | 1 |  |
|  | Tablet containing 75 micrograms anhydrous levothyroxine sodium | 20 | 200 | 1 |  |
|  | Tablet containing 100 micrograms anhydrous levothyroxine sodium | 20 | 200 | 1 |  |
|  | Tablet containing 125 micrograms anhydrous levothyroxine sodium | 20 | 200 | 1 |  |
|  | Tablet containing 200 micrograms anhydrous levothyroxine sodium | 20 | 200 | 1 |  |
| Linagliptin | Tablet 5 mg | 20 | 30 | 5 |  |
| Linagliptin with metformin | Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride | 20 | 60 | 5 |  |
|  | Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride | 20 | 60 | 5 |  |
|  | Tablet containing 2.5 mg linagliptin with 1000 mg metformin hydrochloride | 20 | 60 | 5 |  |
| Liothyronine | Tablet containing liothyronine sodium 20 micrograms | 20 | 100 | 2 |  |
| Lisinopril | Tablet 5 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg | 20 | 30 | 5 |  |
|  | Tablet 20 mg | 20 | 30 | 5 |  |
| Medroxyprogesterone | Injection containing medroxyprogesterone acetate 150 mg in 1 mL pre‑filled syringe | 20 | 1 | 1 |  |
|  | Tablet containing medroxyprogesterone acetate 5 mg | 20 | 56 | 2 |  |
|  | Tablet containing medroxyprogesterone acetate 10 mg | 20 | 30 | 2 |  |
|  |  | 20 | 100 | 2 |  |
| Melatonin | Tablet 1 mg (modified release) | 20 | 60 | 5 |  |
|  | Tablet 5 mg (modified release) | 20 | 30 | 5 |  |
| Meloxicam | Capsule 15 mg | 20 | 30 | 3 |  |
|  | Tablet 15 mg | 20 | 30 | 3 |  |
| Memantine | Tablet containing memantine hydrochloride 10 mg | 20 | 56 | 5 |  |
|  | Tablet containing memantine hydrochloride 20 mg | 20 | 28 | 5 |  |
| Mesalazine | Sachet containing granules, 500 mg per sachet | 20 | 200 | 5 |  |
|  | Sachet containing granules, 1 g per sachet | 20 | 100 | 5 |  |
|  | Sachet containing granules, 1.5 g per sachet | 20 | 60 | 5 |  |
|  | Sachet containing granules, 3 g per sachet | 20 | 30 | 5 |  |
|  | Sachet containing prolonged release granules, 1 g per sachet | 20 | 100 | 5 |  |
|  | Sachet containing prolonged release granules, 2 g per sachet | 20 | 60 | 5 |  |
|  | Sachet containing prolonged release granules, 4 g per sachet | 20 | 30 | 5 |  |
|  | Tablet 250 mg (enteric coated) | 20 | 100 | 5 |  |
|  | Tablet 500 mg (enteric coated) | 20 | 200 | 5 |  |
|  | Tablet 500 mg (prolonged release) | 20 | 200 | 5 |  |
|  | Tablet 800 mg (enteric coated) | 20 | 90 | 5 |  |
|  | Tablet 1 g (enteric coated) | 20 | 120 | 5 |  |
|  | Tablet 1 g (prolonged release) | 20 | 120 | 5 |  |
|  | Tablet 1.2 g (prolonged release) | 20 | 120 | 5 |  |
|  | Tablet 1.6 g (enteric coated) | 20 | 120 | 4 |  |
| Metformin | Tablet containing metformin hydrochloride 500 mg | 20 | 100 | 5 |  |
|  | Tablet containing metformin hydrochloride 850 mg | 20 | 60 | 5 |  |
|  | Tablet containing metformin hydrochloride 1 g | 20 | 90 | 5 |  |
|  | Tablet (extended release) containing metformin hydrochloride 500 mg | 20 | 120 | 5 |  |
|  | Tablet (extended release) containing metformin hydrochloride 1 g | 20 | 60 | 5 |  |
| Methadone | Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 1 L bottle, 1 mL | 20 | 840 | 5 |  |
|  | Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 200 mL bottle, 1 mL | 20 | 840 | 5 |  |
| Methotrexate | Injection 7.5 mg in 0.15 mL pre‑filled syringe | 20 | 4 | 5 |  |
|  | Injection 10 mg in 0.2 mL pre‑filled syringe | 20 | 4 | 5 |  |
|  | Injection 15 mg in 0.3 mL pre‑filled syringe | 20 | 4 | 5 |  |
|  | Injection 20 mg in 0.4 mL pre‑filled syringe | 20 | 4 | 5 |  |
|  | Injection 25 mg in 0.5 mL pre‑filled syringe | 20 | 4 | 5 |  |
|  | Tablet 10 mg | 20 | 10 | 5 |  |
| Methyldopa | Tablet 250 mg (as sesquihydrate) | 20 | 100 | 5 |  |
| Methylprednisolone | Injection containing methylprednisolone acetate 40 mg in 1 mL | 20 | 5 | 0 |  |
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | 20 | 100 | 5 |  |
|  | Tablet containing metoprolol tartrate 100 mg | 20 | 60 | 5 |  |
| Metoprolol succinate | Tablet 47.5 mg (controlled release) | 20 | 30 | 5 |  |
|  | Tablet 95 mg (controlled release) | 20 | 30 | 5 |  |
|  | Tablet 190 mg (controlled release) | 20 | 30 | 5 |  |
| Migalastat | Capsule containing 150 mg migalastat hydrochloride (equivalent to 123 mg migalastat) | 20 | 14 | 5 |  |
| Minocycline | Tablet 50 mg (as hydrochloride) | 20 | 60 | 5 |  |
| Minoxidil | Tablet 10 mg | 20 | 100 | 5 |  |
| Mirtazapine | Tablet 45 mg | 20 | 30 | 5 |  |
|  | Tablet 45 mg (orally disintegrating) | 20 | 30 | 5 |  |
| Moclobemide | Tablet 150 mg | 20 | 60 | 5 |  |
|  | Tablet 300 mg | 20 | 60 | 5 |  |
| Modafinil | Tablet 100 mg | 20 | 120 | 5 |  |
| Momelotinib | Tablet 100 mg (as dihydrochloride monohydrate) | 20 | 30 | 0 |  |
|  |  | 20 | 30 | 5 |  |
|  | Tablet 150 mg (as dihydrochloride monohydrate) | 20 | 30 | 0 |  |
|  |  | 20 | 30 | 5 |  |
|  | Tablet 200 mg (as dihydrochloride monohydrate) | 20 | 30 | 0 |  |
|  |  | 20 | 30 | 5 |  |
| Montelukast | Tablet, chewable, 4 mg (as sodium) | 20 | 28 | 5 |  |
|  | Tablet, chewable, 5 mg (as sodium) | 20 | 28 | 5 |  |
| Moxonidine | Tablet 200 micrograms | 20 | 30 | 5 |  |
|  | Tablet 400 micrograms | 20 | 30 | 5 |  |
| Nafarelin | Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses | 20 | 1 | 5 |  |
| Naproxen | Tablet 750 mg (sustained release) | 20 | 28 | 0 |  |
|  |  | 20 | 28 | 3 |  |
|  | Tablet 1 g (sustained release) | 20 | 28 | 0 |  |
|  |  | 20 | 28 | 3 |  |
| Nebivolol | Tablet 1.25 mg (as hydrochloride) | 20 | 56 | 5 |  |
|  | Tablet 5 mg (as hydrochloride) | 20 | 28 | 5 |  |
|  | Tablet 10 mg (as hydrochloride) | 20 | 28 | 5 |  |
| Nicorandil | Tablets 10 mg, 60 | 20 | 1 | 5 |  |
|  | Tablets 20 mg, 60 | 20 | 1 | 5 |  |
| Nifedipine | Tablet 30 mg (controlled release) | 20 | 30 | 5 |  |
|  | Tablet 60 mg (controlled release) | 20 | 30 | 5 |  |
| Nilotinib | Capsule 150 mg (as hydrochloride monohydrate) | 20 | 120 | 5 |  |
|  | Capsule 200 mg (as hydrochloride monohydrate) | 20 | 120 | 5 |  |
| Nintedanib | Capsule 100 mg | 20 | 60 | 5 |  |
|  | Capsule 150 mg | 20 | 60 | 5 |  |
| Niraparib | Tablet 100 mg (as tosilate monohydrate) | 20 | 56 | 2 |  |
|  |  | 20 | 56 | 5 |  |
|  |  | 20 | 84 | 2 |  |
|  |  | 20 | 84 | 5 |  |
| Nizatidine | Capsule 150 mg | 20 | 60 | 5 |  |
|  | Capsule 300 mg | 20 | 30 | 5 |  |
| Norethisterone | Tablets 350 micrograms, 28 | 20 | 4 | 2 |  |
| Norethisterone with ethinylestradiol | Pack containing 21 tablets 500 micrograms‑35 micrograms and 7 inert tablets | 20 | 4 | 2 |  |
|  | Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets | 20 | 4 | 2 |  |
| Obeticholic acid | Tablet 5 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg | 20 | 30 | 5 |  |
| Ofatumumab | Solution for injection 20 mg in 0.4 mL pre‑filled pen | 20 | 1 | 5 |  |
|  |  | 20 | 3 | 0 |  |
| Olaparib | Tablet 100 mg | 20 | 112 | 5 |  |
|  |  | 20 | 112 | 6 |  |
|  | Tablet 150 mg | 20 | 112 | 5 |  |
|  |  | 20 | 112 | 6 |  |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg | 20 | 30 | 5 |  |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | 20 | 30 | 5 |  |
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | 20 | 30 | 5 |  |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | 20 | 30 | 5 |  |
| Olsalazine | Capsule containing olsalazine sodium 250 mg | 20 | 100 | 5 |  |
|  | Tablet containing olsalazine sodium 500 mg | 20 | 100 | 5 |  |
| Omeprazole | Capsule 20 mg | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 10 mg (as magnesium) | 20 | 30 | 5 |  |
|  | Tablet 20 mg | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 20 mg (as magnesium) | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
| Opicapone | Capsule 50 mg | 20 | 30 | 5 |  |
| Oxcarbazepine | Tablet 600 mg | 20 | 100 | 5 |  |
| Oxybutynin | Tablet containing oxybutynin hydrochloride 5 mg | 20 | 100 | 5 |  |
|  | Transdermal patches 36 mg, 8 | 20 | 1 | 5 |  |
| Ozanimod | Capsule 920 micrograms | 20 | 28 | 3 |  |
|  |  | 20 | 28 | 5 |  |
|  | Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms | 20 | 1 | 0 |  |
| Palbociclib | Tablet 75 mg | 20 | 21 | 5 |  |
|  | Tablet 100 mg | 20 | 21 | 5 |  |
|  | Tablet 125 mg | 20 | 21 | 5 |  |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | 20 | 30 | 5 |  |
|  | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
| Paracetamol | Tablet 500 mg | 20 | 300 | 0 |  |
|  | Tablet 665 mg (modified release) | 20 | 192 | 5 |  |
| Paroxetine | Tablet 20 mg (as hydrochloride) | 20 | 30 | 5 |  |
| Patiromer | Powder for oral suspension 8.4 g | 20 | 30 | 5 |  |
|  | Powder for oral suspension 16.8 g | 20 | 30 | 5 |  |
| Pazopanib | Tablet 200 mg (as hydrochloride) | 20 | 30 | 5 |  |
|  |  | 20 | 90 | 2 |  |
|  |  | 20 | 90 | 5 |  |
|  | Tablet 400 mg (as hydrochloride) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 2 |  |
|  |  | 20 | 60 | 5 |  |
| Perampanel | Tablet 4 mg (as hemisesquihydrate) | 20 | 28 | 5 |  |
|  | Tablet 6 mg (as hemisesquihydrate) | 20 | 28 | 5 |  |
|  | Tablet 8 mg (as hemisesquihydrate) | 20 | 28 | 5 |  |
|  | Tablet 10 mg (as hemisesquihydrate) | 20 | 28 | 5 |  |
|  | Tablet 12 mg (as hemisesquihydrate) | 20 | 28 | 5 |  |
| Perhexiline | Tablet containing perhexiline maleate 100 mg | 20 | 100 | 5 |  |
| Perindopril | Tablet containing perindopril arginine 2.5 mg | 20 | 30 | 5 |  |
|  | Tablet containing perindopril arginine 5 mg | 20 | 30 | 5 |  |
|  | Tablet containing perindopril arginine 10 mg | 20 | 30 | 5 |  |
|  | Tablet containing perindopril erbumine 2 mg | 20 | 30 | 5 |  |
|  | Tablet containing perindopril erbumine 4 mg | 20 | 30 | 5 |  |
|  | Tablet containing perindopril erbumine 8 mg | 20 | 30 | 5 |  |
| Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) | 20 | 30 | 5 |  |
|  | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | 20 | 30 | 5 |  |
|  | Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) | 20 | 30 | 5 |  |
|  | Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) | 20 | 30 | 5 |  |
| Perindopril with indapamide | Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg | 20 | 30 | 5 |  |
|  | Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg | 20 | 30 | 5 |  |
|  | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | 20 | 30 | 5 |  |
| Phenobarbital | Tablet 30 mg | 20 | 200 | 4 |  |
| Phenoxybenzamine | Capsule containing phenoxybenzamine hydrochloride 10 mg | 20 | 100 | 5 |  |
| Phenytoin | Capsule containing phenytoin sodium 30 mg | 20 | 200 | 2 |  |
|  | Capsule containing phenytoin sodium 100 mg | 20 | 200 | 2 |  |
|  | Tablet 50 mg | 20 | 200 | 2 |  |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | 20 | 28 | 5 |  |
| Pirfenidone | Tablet 267 mg | 20 | 270 | 5 |  |
|  | Tablet 801 mg | 20 | 90 | 5 |  |
| Pizotifen | Tablet 500 micrograms (as malate) | 20 | 100 | 2 |  |
| Ponatinib | Tablet 15 mg (as hydrochloride) | 20 | 60 | 2 |  |
|  |  | 20 | 60 | 5 |  |
|  | Tablet 45 mg (as hydrochloride) | 20 | 30 | 2 |  |
|  |  | 20 | 30 | 5 |  |
| Potassium chloride | Tablet 600 mg (sustained release) | 20 | 200 | 1 |  |
| Potassium chloride with potassium bicarbonate | Tablet, effervescent, 14 mmol potassium and 8 mmol chloride | 20 | 60 | 1 |  |
| Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | 20 | 30 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | 20 | 30 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | 20 | 30 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | 20 | 30 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | 20 | 30 | 5 |  |
| Prasugrel | Tablet 5 mg | 20 | 28 | 5 |  |
|  | Tablet 10 mg | 20 | 28 | 5 |  |
| Pravastatin | Tablet containing pravastatin sodium 10 mg | 20 | 30 | 5 |  |
|  | Tablet containing pravastatin sodium 20 mg | 20 | 30 | 5 |  |
|  | Tablet containing pravastatin sodium 40 mg | 20 | 30 | 5 |  |
|  | Tablet containing pravastatin sodium 80 mg | 20 | 30 | 5 |  |
| Prazosin | Capsule 1 mg (as hydrochloride) (S19A) | 20 | 100 | 5 |  |
|  | Tablet 1 mg (as hydrochloride) | 20 | 100 | 5 |  |
|  | Tablet 2 mg (as hydrochloride) | 20 | 100 | 5 |  |
|  | Tablet 5 mg (as hydrochloride) | 20 | 100 | 5 |  |
| Pregabalin | Capsule 300 mg | 20 | 56 | 5 |  |
| Primidone | Tablet 250 mg | 20 | 200 | 2 |  |
| Probenecid | Tablet 500 mg | 20 | 100 | 5 |  |
| Progesterone | Capsule 100 mg | 20 | 30 | 5 |  |
| Progesterone and estradiol | Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses | 20 | 1 | 5 |  |
| Propantheline | Tablet containing propantheline bromide 15 mg | 20 | 200 | 5 |  |
| Propranolol | Tablet containing propranolol hydrochloride 10 mg | 20 | 100 | 5 |  |
|  | Tablet containing propranolol hydrochloride 40 mg | 20 | 100 | 5 |  |
| Quinagolide | Tablet 75 micrograms (as hydrochloride) | 20 | 30 | 5 |  |
| Quinapril | Tablet 5 mg (as hydrochloride) | 20 | 30 | 5 |  |
|  | Tablet 10 mg (as hydrochloride) | 20 | 30 | 5 |  |
|  | Tablet 20 mg (as hydrochloride) | 20 | 30 | 5 |  |
| Quinapril with hydrochlorothiazide | Tablet 10 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide | 20 | 30 | 5 |  |
|  | Tablet 20 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide | 20 | 30 | 5 |  |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | 20 | 28 | 5 |  |
|  | Tablet containing rabeprazole sodium 20 mg (enteric coated) | 20 | 30 | 1 |  |
|  |  | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | 20 | 28 | 5 |  |
| Raltegravir | Tablet 600 mg (as potassium) | 20 | 120 | 5 |  |
| Ramipril | Capsule 1.25 mg | 20 | 30 | 5 |  |
|  | Capsule 2.5 mg | 20 | 30 | 5 |  |
|  | Capsule 5 mg | 20 | 30 | 5 |  |
|  | Capsule 10 mg | 20 | 30 | 5 |  |
|  | Tablet 1.25 mg | 20 | 30 | 5 |  |
|  | Tablet 2.5 mg | 20 | 30 | 5 |  |
|  | Tablet 5 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg | 20 | 30 | 5 |  |
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | 20 | 30 | 5 |  |
|  | Tablet 5 mg‑5 mg (modified release) | 20 | 30 | 5 |  |
| Ranitidine | Tablet 150 mg (as hydrochloride) | 20 | 60 | 5 |  |
|  | Tablet 300 mg (as hydrochloride) | 20 | 30 | 5 |  |
| Rasagiline | Tablet 1 mg (as mesilate) | 20 | 30 | 5 |  |
| Reboxetine | Tablet 4 mg (as mesilate) | 20 | 60 | 5 |  |
| Relugolix with estradiol and with norethisterone | Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 500 micrograms | 20 | 28 | 5 |  |
| Ribociclib | Tablet 200 mg | 20 | 21 | 5 |  |
|  |  | 20 | 42 | 5 |  |
|  |  | 20 | 63 | 5 |  |
| Rifaximin | Tablet 550 mg | 20 | 56 | 5 |  |
| Riluzole | Tablet 50 mg | 20 | 56 | 5 |  |
| Ripretinib | Tablet 50 mg | 20 | 90 | 1 |  |
| Risankizumab | Injection 150 mg in 1 mL pre‑filled pen | 20 | 1 | 1 |  |
|  |  | 20 | 1 | 2 |  |
| Risedronic acid | Tablet containing risedronate sodium 5 mg | 20 | 28 | 5 |  |
|  | Tablet containing risedronate sodium 30 mg | 20 | 28 | 1 |  |
|  | Tablet containing risedronate sodium 35 mg | 20 | 4 | 5 |  |
|  | Tablet containing risedronate sodium 150 mg | 20 | 1 | 5 |  |
|  | Tablet (enteric coated) containing risedronate sodium 35 mg | 20 | 4 | 5 |  |
| Rivaroxaban | Tablet 2.5 mg | 20 | 60 | 5 |  |
|  | Tablet 10 mg | 20 | 30 | 5 |  |
|  | Tablet 15 mg | 20 | 28 | 5 |  |
|  | Tablet 20 mg | 20 | 28 | 5 |  |
| Rivastigmine | Capsule 1.5 mg (as hydrogen tartrate) | 20 | 56 | 5 |  |
|  | Capsule 3 mg (as hydrogen tartrate) | 20 | 56 | 5 |  |
|  | Capsule 4.5 mg (as hydrogen tartrate) | 20 | 56 | 5 |  |
|  | Capsule 6 mg (as hydrogen tartrate) | 20 | 56 | 5 |  |
|  | Transdermal patch 9 mg | 20 | 30 | 5 |  |
|  | Transdermal patch 18 mg | 20 | 30 | 5 |  |
|  | Transdermal patch 27 mg | 20 | 30 | 5 |  |
| Romosozumab | Injection 105 mg in 1.17 mL single use pre‑filled syringe | 20 | 2 | 5 |  |
| Rosuvastatin | Tablet 5 mg (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 10 mg (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 20 mg (as calcium) | 20 | 30 | 5 |  |
|  | Tablet 40 mg (as calcium) | 20 | 30 | 5 |  |
| Rotigotine | Transdermal patch 4.5 mg | 20 | 28 | 5 |  |
|  | Transdermal patch 9 mg | 20 | 28 | 5 |  |
|  | Transdermal patch 13.5 mg | 20 | 28 | 5 |  |
|  | Transdermal patch 18 mg | 20 | 28 | 5 |  |
| Ruxolitinib | Tablet 5 mg | 20 | 56 | 5 |  |
|  |  | 20 | 112 | 0 |  |
|  |  | 20 | 112 | 5 |  |
|  | Tablet 10 mg | 20 | 56 | 0 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 15 mg | 20 | 56 | 0 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 20 mg | 20 | 56 | 0 |  |
|  |  | 20 | 56 | 5 |  |
| Sacubitril with valsartan | Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg | 20 | 56 | 5 |  |
|  | Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg | 20 | 56 | 5 |  |
|  | Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg | 20 | 56 | 5 |  |
| Safinamide | Tablet 50 mg | 20 | 30 | 5 |  |
|  | Tablet 100 mg | 20 | 30 | 5 |  |
| Sapropterin | Powder for oral solution 500 mg (as dihydrochloride) | 20 | 30 | 5 |  |
|  | Tablet (soluble) containing sapropterin dihydrochloride 100 mg | 20 | 180 | 5 |  |
| Saxagliptin | Tablet 2.5 mg (as hydrochloride) | 20 | 28 | 5 |  |
|  | Tablet 5 mg (as hydrochloride) | 20 | 28 | 5 |  |
| Saxagliptin with dapagliflozin | Tablet containing saxagliptin 5 mg with dapaglifozin 10 mg | 20 | 28 | 5 |  |
| Saxagliptin with metformin | Tablet (modified release) containing 2.5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | 20 | 56 | 5 |  |
|  | Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 500 mg metformin hydrochloride | 20 | 28 | 5 |  |
|  | Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | 20 | 28 | 5 |  |
| Secukinumab | Injection 150 mg in 1 mL pre‑filled pen | 20 | 1 | 5 |  |
|  |  | 20 | 2 | 3 |  |
|  |  | 20 | 2 | 5 |  |
|  |  | 20 | 8 | 0 |  |
| Selegiline | Tablet containing selegiline hydrochloride 5 mg | 20 | 100 | 5 |  |
| Selpercatinib | Capsule 40 mg | 20 | 56 | 5 |  |
|  | Capsule 80 mg | 20 | 112 | 5 |  |
| Selumetinib | Capsule 10 mg | 20 | 60 | 5 |  |
|  | Capsule 25 mg | 20 | 60 | 5 |  |
| Sertraline | Tablet 50 mg (as hydrochloride) | 20 | 30 | 5 |  |
|  | Tablet 100 mg (as hydrochloride) | 20 | 30 | 5 |  |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | 20 | 180 | 5 |  |
|  | Tablet containing sevelamer hydrochloride 800 mg | 20 | 180 | 5 |  |
| Simvastatin | Tablet 5 mg | 20 | 30 | 5 |  |
|  | Tablet 10 mg | 20 | 30 | 5 |  |
|  | Tablet 20 mg | 20 | 30 | 5 |  |
|  | Tablet 40 mg | 20 | 30 | 5 |  |
|  | Tablet 80 mg | 20 | 30 | 5 |  |
| Siponimod | Tablet 250 micrograms (as hemifumarate) | 20 | 120 | 5 |  |
|  | Tablet 1 mg (as hemifumarate) | 20 | 28 | 5 |  |
|  | Tablet 2 mg (as hemifumarate) | 20 | 28 | 5 |  |
| Sitagliptin | Tablet 25 mg | 20 | 28 | 5 |  |
|  | Tablet 50 mg | 20 | 28 | 5 |  |
|  | Tablet 100 mg | 20 | 28 | 5 |  |
| Sitagliptin with metformin | Tablet containing 50 mg sitagliptin with 500 mg metformin hydrochloride | 20 | 56 | 5 |  |
|  | Tablet containing 50 mg sitagliptin with 850 mg metformin hydrochloride | 20 | 56 | 5 |  |
|  | Tablet containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | 20 | 56 | 5 |  |
|  | Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | 20 | 56 | 5 |  |
|  | Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride | 20 | 28 | 5 |  |
| Sonidegib | Capsule 200 mg | 20 | 30 | 3 |  |
| Sorafenib | Tablet 200 mg (as tosilate) | 20 | 120 | 2 |  |
|  |  | 20 | 120 | 5 |  |
| Spironolactone | Tablet 25 mg | 20 | 100 | 5 |  |
|  | Tablet 100 mg | 20 | 100 | 5 |  |
| Sulfasalazine | Tablet 500 mg | 20 | 200 | 5 |  |
|  | Tablet 500 mg (enteric coated) | 20 | 200 | 5 |  |
| Sulthiame | Tablet 50 mg | 20 | 200 | 2 |  |
|  | Tablet 200 mg | 20 | 200 | 2 |  |
| Sunitinib | Capsule 12.5 mg | 20 | 28 | 1 |  |
|  |  | 20 | 28 | 2 |  |
|  |  | 20 | 28 | 3 |  |
|  |  | 20 | 28 | 5 |  |
|  | Capsule 25 mg | 20 | 28 | 1 |  |
|  |  | 20 | 28 | 2 |  |
|  |  | 20 | 28 | 3 |  |
|  |  | 20 | 28 | 5 |  |
|  | Capsule 37.5 mg | 20 | 28 | 1 |  |
|  |  | 20 | 28 | 2 |  |
|  |  | 20 | 28 | 3 |  |
|  |  | 20 | 28 | 5 |  |
|  | Capsule 50 mg | 20 | 28 | 1 |  |
|  |  | 20 | 28 | 2 |  |
|  |  | 20 | 28 | 3 |  |
|  |  | 20 | 28 | 5 |  |
| Tafamidis | Capsule 61 mg | 20 | 30 | 5 |  |
| Talazoparib | Capsule 100 micrograms (as tosilate) | 20 | 30 | 5 |  |
|  | Capsule 250 micrograms (as tosilate) | 20 | 30 | 5 |  |
|  | Capsule 350 micrograms (as tosilate) | 20 | 30 | 5 |  |
|  | Capsule 500 micrograms (as tosilate) | 20 | 30 | 5 |  |
| Tamoxifen | Tablet 20 mg (as citrate) | 20 | 30 | 5 |  |
|  |  | 20 | 60 | 5 |  |
| Teduglutide | Powder for injection 5 mg with diluent | 20 | 28 | 0 |  |
|  |  | 20 | 28 | 5 |  |
|  |  | 20 | 28 | 11 |  |
| Telmisartan | Tablet 40 mg | 20 | 28 | 5 |  |
|  | Tablet 80 mg | 20 | 28 | 5 |  |
| Telmisartan with amlodipine | Tablet 40 mg‑5 mg (as besilate) | 20 | 28 | 5 |  |
|  | Tablet 40 mg‑10 mg (as besilate) | 20 | 28 | 5 |  |
|  | Tablet 80 mg‑5 mg (as besilate) | 20 | 28 | 5 |  |
|  | Tablet 80 mg‑10 mg (as besilate) | 20 | 28 | 5 |  |
| Telmisartan with hydrochlorothiazide | Tablet 40 mg‑12.5 mg | 20 | 28 | 5 |  |
|  | Tablet 80 mg‑12.5 mg | 20 | 28 | 5 |  |
|  | Tablet 80 mg‑25 mg | 20 | 28 | 5 |  |
| Temozolomide | Capsule 5 mg | 20 | 5 | 5 |  |
|  |  | 20 | 15 | 2 |  |
|  | Capsule 20 mg | 20 | 5 | 5 |  |
|  |  | 20 | 15 | 2 |  |
|  | Capsule 100 mg | 20 | 5 | 5 |  |
|  |  | 20 | 15 | 2 |  |
|  | Capsule 140 mg | 20 | 5 | 5 |  |
|  |  | 20 | 15 | 2 |  |
|  | Capsule 180 mg | 20 | 5 | 5 |  |
|  | Capsule 250 mg | 20 | 5 | 5 |  |
| Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat | Tablet containing tenofovir alafenamide 10 mg with emtricitabine 200 mg, elvitegravir 150 mg and cobicistat 150 mg | 20 | 60 | 5 |  |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | 20 | 30 | 2 |  |
|  | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | 20 | 30 | 2 |  |
| Terbinafine | Tablet 250 mg (as hydrochloride) | 20 | 42 | 0 |  |
|  |  | 20 | 42 | 1 |  |
| Teriflunomide | Tablet 14 mg | 20 | 28 | 5 |  |
| Teriparatide | Injection 250 micrograms per mL, 2.4 mL in multi‑dose pre‑filled pen | 20 | 1 | 5 |  |
| Testosterone | I.M. injection containing testosterone undecanoate 1,000 mg in 4 mL | 20 | 1 | 1 |  |
|  | Transdermal cream 50 mg per mL, 50 mL | 20 | 1 | 1 |  |
|  | Transdermal gel 50 mg in 5 g sachet, 30 | 20 | 1 | 5 |  |
|  | Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2 | 20 | 1 | 4 |  |
|  | Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses | 20 | 1 | 5 |  |
| Tetrabenazine | Tablet 25 mg | 20 | 112 | 5 |  |
| Theophylline | Tablet 200 mg (sustained release) | 20 | 100 | 5 |  |
|  | Tablet 250 mg (sustained release) | 20 | 100 | 5 |  |
|  | Tablet 300 mg (sustained release) | 20 | 100 | 5 |  |
| Tiagabine | Tablet 5 mg (as hydrochloride) | 20 | 100 | 5 |  |
|  | Tablet 10 mg (as hydrochloride) | 20 | 100 | 5 |  |
|  | Tablet 15 mg (as hydrochloride) | 20 | 100 | 5 |  |
| Ticagrelor | Tablet 90 mg | 20 | 56 | 5 |  |
| Tiotropium | Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device) | 20 | 30 | 5 |  |
|  | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler) | 20 | 30 | 5 |  |
|  | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in LupinHaler) | 20 | 30 | 5 |  |
|  | Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations) | 20 | 1 | 5 |  |
| Tiotropium with olodaterol | Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses | 20 | 1 | 5 |  |
| Tocilizumab | Injection 162 mg in 0.9 mL single use pre‑filled pen | 20 | 4 | 5 |  |
|  |  | 20 | 4 | 6 |  |
|  | Injection 162 mg in 0.9 mL single use pre‑filled syringe | 20 | 4 | 5 |  |
|  |  | 20 | 4 | 6 |  |
| Tofacitinib | Tablet 5 mg | 20 | 56 | 3 |  |
|  |  | 20 | 56 | 5 |  |
|  | Tablet 10 mg | 20 | 56 | 3 |  |
|  |  | 20 | 56 | 5 |  |
| Topiramate | Capsule 15 mg | 20 | 60 | 5 |  |
|  | Capsule 25 mg | 20 | 60 | 5 |  |
|  | Capsule 50 mg | 20 | 60 | 5 |  |
|  | Tablet 25 mg | 20 | 60 | 5 |  |
|  | Tablet 50 mg | 20 | 60 | 5 |  |
|  | Tablet 100 mg | 20 | 60 | 5 |  |
|  | Tablet 200 mg | 20 | 60 | 5 |  |
| Trandolapril | Capsule 500 micrograms | 20 | 28 | 5 |  |
|  | Capsule 1 mg | 20 | 28 | 5 |  |
|  | Capsule 2 mg | 20 | 28 | 5 |  |
|  | Capsule 4 mg | 20 | 28 | 5 |  |
| Trandolapril with verapamil | Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) | 20 | 28 | 5 |  |
|  | Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) | 20 | 28 | 5 |  |
| Triamcinolone | Injection containing triamcinolone acetonide 10 mg in 1 mL | 20 | 5 | 0 |  |
| Trientine | Capsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine) | 20 | 200 | 5 |  |
| Trihexyphenidyl | Tablet containing trihexyphenidyl hydrochloride 2 mg | 20 | 200 | 2 |  |
|  | Tablet containing trihexyphenidyl hydrochloride 5 mg | 20 | 200 | 1 |  |
| Triptorelin | Powder for I.M. injection (prolonged release) 3.75 mg (as embonate) with solvent, syringe and needles | 20 | 1 | 5 |  |
|  | Powder for I.M. injection (prolonged release) 11.25 mg (as embonate) with solvent, syringe and needles | 20 | 1 | 1 |  |
|  | Powder for I.M. injection (prolonged release) 22.5 mg (as embonate) with solvent, syringe and needles | 20 | 1 | 0 |  |
| Umeclidinium | Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses | 20 | 1 | 5 |  |
| Umeclidinium with vilanterol | Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | 20 | 1 | 5 |  |
| Upadacitinib | Tablet 15 mg | 20 | 28 | 1 |  |
|  |  | 20 | 28 | 3 |  |
|  |  | 20 | 28 | 4 |  |
|  |  | 20 | 28 | 5 |  |
|  | Tablet 30 mg | 20 | 28 | 1 |  |
|  |  | 20 | 28 | 2 |  |
|  |  | 20 | 28 | 3 |  |
|  |  | 20 | 28 | 4 |  |
|  |  | 20 | 28 | 5 |  |
|  | Tablet 45 mg | 20 | 28 | 2 |  |
|  |  | 20 | 28 | 3 |  |
| Ustekinumab | Injection 45 mg in 0.5 mL | 20 | 1 | 0 |  |
|  |  | 20 | 1 | 1 |  |
|  |  | 20 | 1 | 2 |  |
|  |  | 20 | 2 | 0 |  |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | 20 | 30 | 5 |  |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | 20 | 200 | 2 |  |
|  | Tablet (enteric coated) containing sodium valproate 500 mg | 20 | 200 | 2 |  |
| Valsartan | Tablet 80 mg | 20 | 28 | 5 |  |
|  | Tablet 160 mg | 20 | 28 | 5 |  |
|  | Tablet 320 mg | 20 | 28 | 5 |  |
| Valsartan with hydrochlorothiazide | Tablet 80 mg‑12.5 mg | 20 | 28 | 5 |  |
|  | Tablet 160 mg‑12.5 mg | 20 | 28 | 5 |  |
|  | Tablet 160 mg‑25 mg | 20 | 28 | 5 |  |
|  | Tablet 320 mg‑12.5 mg | 20 | 28 | 5 |  |
|  | Tablet 320 mg‑25 mg | 20 | 28 | 5 |  |
| Varenicline | Box containing 11 tablets 0.5 mg and 42 tablets 1 mg | 20 | 1 | 0 |  |
|  | Tablet 1 mg | 20 | 56 | 2 |  |
|  |  | 20 | 112 | 0 |  |
| Vedolizumab | Injection 108 mg in 0.68 mL single use pre‑filled pen | 20 | 2 | 0 |  |
|  |  | 20 | 2 | 5 |  |
| Venetoclax | Tablet 100 mg | 20 | 120 | 2 |  |
|  |  | 20 | 120 | 4 |  |
|  |  | 20 | 120 | 5 |  |
| Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | 20 | 28 | 5 |  |
|  | Capsule (modified release) 150 mg (as hydrochloride) | 20 | 28 | 5 |  |
| Verapamil | Tablet containing verapamil hydrochloride 80 mg | 20 | 100 | 5 |  |
|  | Tablet containing verapamil hydrochloride 180 mg (sustained release) | 20 | 30 | 5 |  |
|  | Tablet containing verapamil hydrochloride 240 mg (sustained release) | 20 | 30 | 5 |  |
| Vigabatrin | Oral powder, sachet 500 mg | 20 | 60 | 5 |  |
|  | Tablet 500 mg | 20 | 100 | 5 |  |
| Vildagliptin | Tablet 50 mg | 20 | 60 | 5 |  |
| Vildagliptin with metformin | Tablet containing 50 mg vildagliptin with 500 mg metformin hydrochloride | 20 | 60 | 5 |  |
|  | Tablet containing 50 mg vildagliptin with 850 mg metformin hydrochloride | 20 | 60 | 5 |  |
|  | Tablet containing 50 mg vildagliptin with 1000 mg metformin hydrochloride | 20 | 60 | 5 |  |
| Vismodegib | Capsule 150 mg | 20 | 28 | 3 |  |
| Vosoritide | Powder for injection 400 micrograms with diluent | 20 | 30 | 5 |  |
|  | Powder for injection 560 micrograms with diluent | 20 | 30 | 5 |  |
|  | Powder for injection 1.2 mg with diluent | 20 | 30 | 5 |  |
| Zanubrutinib | Capsule 80 mg | 20 | 120 | 5 |  |
| Zonisamide | Capsule 25 mg | 20 | 56 | 5 |  |
|  | Capsule 50 mg | 20 | 56 | 5 |  |
|  | Capsule 100 mg | 20 | 112 | 5 |  |

Schedule 2—Pharmaceutical items and circumstances specified under subsection 84AAA(2) for purposes of early supply– increased maximum quantity or number of units

| **Listed drug** | **Form** | **Period**  **(days)** | **Circumstances:** | | |
| --- | --- | --- | --- | --- | --- |
| **Maximum quantity or number of units** | **Maximum number of repeats** | **Other circumstances (if any)** |
| Acarbose | Tablet 50 mg | 50 | 180 | 5 |  |
|  | Tablet 50 mg (S19A) | 50 | 180 | 5 |  |
|  | Tablet 100 mg | 50 | 180 | 5 |  |
|  | Tablet 100 mg (S19A) | 50 | 180 | 5 |  |
| Aclidinium | Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses | 50 | 2 | 5 |  |
| Aclidinium with formoterol | Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | 50 | 2 | 5 |  |
| Adapalene with benzoyl peroxide | Gel 1 mg‑25 mg per g, 30 g | 50 | 2 | 3 |  |
| Alendronic acid | Tablet 70 mg (as alendronate sodium) | 50 | 8 | 5 |  |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | 50 | 8 | 5 |  |
|  | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | 50 | 8 | 5 |  |
| Allopurinol | Tablet 100 mg | 50 | 400 | 2 |  |
|  | Tablet 300 mg | 50 | 120 | 2 |  |
| Alogliptin | Tablet 6.25 mg (as benzoate) | 50 | 56 | 5 |  |
|  | Tablet 12.5 mg (as benzoate) | 50 | 56 | 5 |  |
|  | Tablet 25 mg (as benzoate) | 50 | 56 | 5 |  |
| Alogliptin with metformin | Tablet containing 12.5 mg alogliptin (as benzoate) with 500 mg metformin hydrochloride | 50 | 112 | 5 |  |
|  | Tablet containing 12.5 mg alogliptin (as benzoate) with 850 mg metformin hydrochloride | 50 | 112 | 5 |  |
|  | Tablet containing 12.5 mg alogliptin (as benzoate) with 1 g metformin hydrochloride | 50 | 112 | 5 |  |
| Amantadine | Capsule containing amantadine hydrochloride 100 mg | 50 | 200 | 5 |  |
| Amlodipine | Tablet 5 mg (as besilate) | 50 | 60 | 5 |  |
|  | Tablet 10 mg (as besilate) | 50 | 60 | 5 |  |
| Amlodipine with atorvastatin | Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | 50 | 60 | 5 |  |
| Amlodipine with valsartan | Tablet 5 mg (as besilate)‑80 mg | 50 | 56 | 5 |  |
|  | Tablet 5 mg (as besilate)‑160 mg | 50 | 56 | 5 |  |
|  | Tablet 5 mg (as besilate)‑320 mg | 50 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑160 mg | 50 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑320 mg | 50 | 56 | 5 |  |
| Amlodipine with valsartan and hydrochlorothiazide | Tablet 5 mg (as besilate)‑160 mg‑12.5 mg | 50 | 56 | 5 |  |
|  | Tablet 5 mg (as besilate)‑160 mg‑25 mg | 50 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑160 mg‑12.5 mg | 50 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑160 mg‑25 mg | 50 | 56 | 5 |  |
|  | Tablet 10 mg (as besilate)‑320 mg‑25 mg | 50 | 56 | 5 |  |
| Anastrozole | Tablet 1 mg | 50 | 60 | 5 |  |
| Apixaban | Tablet 2.5 mg | 50 | 120 | 5 |  |
|  | Tablet 5 mg | 50 | 120 | 5 |  |
| Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 50 mg in 5 mL | 50 | 360 | 5 |  |
|  | Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL | 50 | 180 | 5 |  |
|  | Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre-filled syringe | 50 | 360 | 5 |  |
|  | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre-filled pen | 50 | 200 | 5 |  |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | 50 | 2 | 5 |  |
|  | Tablet 50 mg | 50 | 60 | 5 |  |
| Atorvastatin | Tablet 10 mg (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 20 mg (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 40 mg (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 80 mg (as calcium) | 50 | 60 | 5 |  |
| Baclofen | Tablet 10 mg | 50 | 200 | 5 |  |
|  | Tablet 25 mg | 50 | 200 | 5 |  |
| Balsalazide | Capsule containing balsalazide sodium 750 mg | 50 | 560 | 5 |  |
| Beclometasone | Pressurised inhalation containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation) | 50 | 2 | 5 |  |
|  | Pressurised inhalation containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation) | 50 | 2 | 5 |  |
|  | Pressurised inhalation in breath actuated device containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation) | 50 | 2 | 5 |  |
|  | Pressurised inhalation in breath actuated device containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation) | 50 | 2 | 5 |  |
| Beclometasone with formoterol | Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose,120 dose | 50 | 2 | 5 |  |
|  | Pressurised inhalation containing beclometasone dipropionate 200 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | 50 | 2 | 5 |  |
| Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses | 50 | 2 | 5 |  |
| Betaxolol | Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL | 50 | 2 | 5 |  |
| Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | 50 | 2 | 5 |  |
|  | Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30 | 50 | 2 | 5 |  |
| Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL | 50 | 2 | 5 |  |
|  | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30 | 50 | 2 | 5 |  |
| Bisacodyl | Suppositories 10 mg, 10 | 50 | 6 | 5 |  |
|  | Suppositories 10 mg, 12 | 50 | 6 | 4 |  |
|  | Tablet 5 mg | 50 | 400 | 2 |  |
| Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | 50 | 56 | 5 |  |
|  | Tablet containing bisoprolol fumarate 5 mg | 50 | 56 | 5 |  |
|  | Tablet containing bisoprolol fumarate 10 mg | 50 | 56 | 5 |  |
| Brimonidine | Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL | 50 | 2 | 5 |  |
|  | Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | 50 | 2 | 5 |  |
| Brimonidine with timolol | Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL | 50 | 2 | 5 |  |
| Brinzolamide | Eye drops 10 mg per mL, 5 mL | 50 | 2 | 5 |  |
| Brinzolamide with brimonidine | Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL,  5 mL | 50 | 2 | 5 |  |
| Brinzolamide with timolol | Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL | 50 | 2 | 5 |  |
| Bromocriptine | Tablet 2.5 mg (as mesilate) | 50 | 120 | 5 |  |
| Budesonide | Nebuliser suspension 1 mg in 2 mL single dose units, 30 | 50 | 2 | 5 |  |
|  | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses | 50 | 2 | 5 |  |
| Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | 50 | 4 | 5 |  |
|  | Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | 50 | 4 | 5 |  |
|  | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | 50 | 4 | 5 |  |
| Budesonide with glycopyrronium and formoterol | Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | 50 | 2 | 5 |  |
| Cabergoline | Tablet 500 micrograms | 50 | 16 | 5 |  |
|  | Tablet 1 mg | 50 | 60 | 5 |  |
|  | Tablet 2 mg | 50 | 60 | 5 |  |
| Calcipotriol with betamethasone | Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g | 50 | 2 | 1 |  |
|  | Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g | 50 | 2 | 1 |  |
| Calcitriol | Capsule 0.25 microgram | 50 | 200 | 3 |  |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | 50 | 480 | 1 |  |
|  | Tablet 600 mg (as carbonate) | 50 | 480 | 1 |  |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | 50 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 8 mg | 50 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 16 mg | 50 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 32 mg | 50 | 60 | 5 |  |
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | 50 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | 50 | 60 | 5 |  |
|  | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | 50 | 60 | 5 |  |
| Carbamazepine | Oral suspension 100 mg per 5 mL, 300 mL | 50 | 2 | 5 |  |
|  | Tablet 100 mg | 50 | 400 | 2 |  |
|  | Tablet 200 mg | 50 | 400 | 2 |  |
|  | Tablet 200 mg (controlled release) | 50 | 400 | 2 |  |
|  | Tablet 400 mg (controlled release) | 50 | 400 | 2 |  |
| Carbimazole | Tablet 5 mg | 50 | 400 | 2 |  |
| Carbomer | Eye gel 2 mg per g, 10 g | 50 | 2 | 5 |  |
|  | Eye gel 2 mg per g, single dose units 0.6 mL, 30 | 50 | 6 | 5 |  |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 10 mL | 50 | 2 | 5 |  |
| Carvedilol | Tablet 6.25 mg | 50 | 120 | 5 |  |
|  | Tablet 12.5 mg | 50 | 120 | 5 |  |
|  | Tablet 25 mg | 50 | 120 | 5 |  |
| Chlortalidone | Tablet 25 mg | 50 | 200 | 1 |  |
| Ciclesonide | Pressurised inhalation 80 micrograms per dose, 120 doses (CFC-free formulation) | 50 | 2 | 5 |  |
|  | Pressurised inhalation 160 micrograms per dose, 120 doses (CFC-free formulation) | 50 | 2 | 5 |  |
| Ciclosporin | Capsule 10 mg | 50 | 240 | 3 |  |
|  | Capsule 25 mg | 50 | 120 | 3 |  |
|  | Capsule 50 mg | 50 | 120 | 3 |  |
|  | Capsule 100 mg | 50 | 120 | 3 |  |
|  | Oral liquid 100 mg per mL, 50 mL | 50 | 4 | 3 |  |
| Citalopram | Tablet 10 mg (as hydrobromide) | 50 | 56 | 2 |  |
|  | Tablet 20 mg (as hydrobromide) | 50 | 56 | 2 |  |
|  | Tablet 40 mg (as hydrobromide) | 50 | 56 | 2 |  |
| Clonidine | Tablet containing clonidine hydrochloride 100 micrograms | 50 | 200 | 5 |  |
|  | Tablet containing clonidine hydrochloride 150 micrograms | 50 | 200 | 5 |  |
| Clopidogrel | Tablet 75 mg (as besilate) | 50 | 56 | 5 |  |
|  | Tablet 75 mg (as hydrogen sulfate) | 50 | 56 | 5 |  |
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)‑100 mg | 50 | 60 | 5 |  |
| Colestyramine | Sachets containing 4.7 g oral powder (equivalent to 4 g colestyramine), 50 | 50 | 4 | 5 |  |
| Cortisone | Tablet containing cortisone acetate 5 mg | 50 | 100 | 4 |  |
|  | Tablet containing cortisone acetate 25 mg | 50 | 120 | 4 |  |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | 50 | 40 | 5 |  |
|  |  | 50 | 200 | 5 |  |
|  | Tablet containing cyproterone acetate 100 mg | 50 | 100 | 5 |  |
| Dabigatran etexilate | Capsule 110 mg (as mesilate) | 50 | 120 | 5 |  |
|  | Capsule 150 mg (as mesilate) | 50 | 120 | 5 |  |
| Dapagliflozin | Tablet 10 mg (as propanediol monohydrate) | 50 | 56 | 5 |  |
| Dapagliflozin with metformin | Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride | 50 | 112 | 5 |  |
|  | Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride | 50 | 56 | 5 |  |
|  | Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride | 50 | 56 | 5 |  |
| Dapagliflozin with sitagliptin | Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 100 mg sitagliptin (as phosphate monohydrate) | 50 | 56 | 5 |  |
| Desmopressin | Tablet containing desmopressin acetate 200 micrograms | 50 | 60 | 5 |  |
|  |  | 50 | 180 | 5 |  |
|  | Wafer 120 micrograms (as acetate) | 50 | 60 | 5 |  |
|  | Wafer 240 micrograms (as acetate) | 50 | 60 | 5 |  |
| Desvenlafaxine | Tablet (extended release) 100 mg (as succinate) | 50 | 56 | 2 |  |
|  | Tablet (extended release) 50 mg (as succinate) | 50 | 56 | 2 |  |
|  | Tablet (modified release) 100 mg | 50 | 56 | 2 |  |
|  | Tablet (modified release) 100 mg (as benzoate) | 50 | 56 | 2 |  |
|  | Tablet (modified release) 50 mg | 50 | 56 | 2 |  |
|  | Tablet (modified release) 50 mg (as benzoate) | 50 | 56 | 2 |  |
| Dexamethasone | Tablet 500 micrograms | 50 | 60 | 4 |  |
| Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | 50 | 60 | 5 |  |
|  | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | 50 | 60 | 5 |  |
|  | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | 50 | 60 | 5 |  |
|  | Tablet containing diltiazem hydrochloride 60 mg | 50 | 180 | 5 |  |
| Dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL | 50 | 2 | 5 |  |
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | 50 | 2 | 5 |  |
| Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | 50 | 56 | 2 |  |
|  | Capsule 50 mg (as hyclate) (containing enteric coated pellets) | 50 | 50 | 2 |  |
|  | Tablet 100 mg (as hyclate) | 50 | 56 | 2 |  |
|  | Tablet 100 mg (as monohydrate) | 50 | 56 | 2 |  |
|  | Tablet 50 mg (as hyclate) | 50 | 50 | 2 |  |
|  | Tablet 50 mg (as monohydrate) | 50 | 50 | 2 |  |
| Duloxetine | Capsule 60 mg (as hydrochloride) | 50 | 56 | 2 |  |
| Dutasteride | Capsule 500 micrograms | 50 | 60 | 5 |  |
| Dutasteride with tamsulosin | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms | 50 | 60 | 5 |  |
| Empagliflozin | Tablet 10 mg | 50 | 60 | 5 |  |
|  | Tablet 25 mg | 50 | 60 | 5 |  |
| Empagliflozin with linagliptin | Tablet containing 10 mg empagliflozin with 5 mg linagliptin | 50 | 60 | 5 |  |
|  | Tablet containing 25 mg empagliflozin with 5 mg linagliptin | 50 | 60 | 5 |  |
| Empagliflozin with metformin | Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride | 50 | 120 | 5 |  |
|  | Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride | 50 | 120 | 5 |  |
|  | Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride | 50 | 120 | 5 |  |
|  | Tablet containing 12.5 mg empagliflozin with 1 g metformin hydrochloride | 50 | 120 | 5 |  |
| Enalapril | Tablet containing enalapril maleate 5 mg | 50 | 60 | 5 |  |
|  | Tablet containing enalapril maleate 10 mg | 50 | 60 | 5 |  |
|  | Tablet containing enalapril maleate 20 mg | 50 | 60 | 5 |  |
| Enalapril with hydrochlorothiazide | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | 50 | 60 | 5 |  |
| Entacapone | Tablet 200 mg | 50 | 400 | 4 |  |
| Eplerenone | Tablet 25 mg | 50 | 60 | 5 |  |
|  | Tablet 50 mg | 50 | 60 | 5 |  |
| Eprosartan | Tablet 600 mg (as mesilate) | 50 | 56 | 5 |  |
| Eprosartan with hydrochlorothiazide | Tablet 600 mg eprosartan (as mesilate) with 12.5 mg hydrochlorothiazide | 50 | 56 | 5 |  |
| Erythromycin | Capsule 250 mg (containing enteric coated pellets) | 50 | 100 | 2 |  |
| Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | 50 | 2 | 2 |  |
|  | Tablet 10 mg (as oxalate) | 50 | 56 | 2 |  |
|  | Tablet 20 mg (as oxalate) | 50 | 56 | 2 |  |
| Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
|  | Capsule (enteric) 40 mg (as magnesium) | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
|  | Tablet (enteric coated) 20 mg (as magnesium) | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
|  | Tablet (enteric coated) 40 mg (as magnesium) | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
| Estradiol | Pessary (modified release) 10 micrograms (as hemihydrate) | 50 | 36 | 2 |  |
|  | Tablet 2 mg | 50 | 112 | 2 |  |
|  | Tablet containing estradiol valerate 1 mg | 50 | 112 | 2 |  |
|  | Tablet containing estradiol valerate 2 mg | 50 | 112 | 2 |  |
|  | Transdermal gel (pump pack) 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses | 50 | 2 | 5 |  |
|  | Transdermal gel 500 micrograms in 0.5 g sachet, 28 | 50 | 2 | 5 |  |
|  | Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28 | 50 | 2 | 5 |  |
| Estradiol and estradiol with dydrogesterone | Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg | 50 | 2 | 5 |  |
|  | Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg | 50 | 2 | 5 |  |
| Estradiol and estradiol with norethisterone | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate | 50 | 2 | 5 |  |
|  | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate | 50 | 2 | 5 |  |
| Estradiol with norethisterone | Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 | 50 | 2 | 5 |  |
|  | Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A) | 50 | 2 | 5 |  |
|  | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 | 50 | 2 | 5 |  |
|  | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A) | 50 | 2 | 5 |  |
| Estriol | Pessaries 500 micrograms, 15 | 50 | 2 | 2 |  |
|  | Vaginal cream 1 mg per g, 15 g | 50 | 2 | 1 |  |
| Ethosuximide | Oral solution 250 mg per 5 mL, 200 mL | 50 | 2 | 5 |  |
| Everolimus | Tablet 0.75 mg | 50 | 240 | 3 |  |
|  | Tablet 1 mg | 50 | 240 | 3 |  |
| Exemestane | Tablet 25 mg | 50 | 60 | 5 |  |
| Ezetimibe | Tablet 10 mg | 50 | 60 | 5 |  |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | 50 | 2 | 5 |  |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | 50 | 2 | 5 |  |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | 50 | 2 | 5 |  |
|  | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | 50 | 2 | 5 |  |
| Ezetimibe with atorvastatin | Tablet 10 mg‑10 mg | 50 | 60 | 5 |  |
|  | Tablet 10 mg‑20 mg | 50 | 60 | 5 |  |
|  | Tablet 10 mg‑40 mg | 50 | 60 | 5 |  |
|  | Tablet 10 mg‑80 mg | 50 | 60 | 5 |  |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | 50 | 60 | 5 |  |
|  | Tablet 10 mg‑20 mg | 50 | 60 | 5 |  |
|  | Tablet 10 mg‑40 mg | 50 | 60 | 5 |  |
|  | Tablet 10 mg‑80 mg | 50 | 60 | 5 |  |
| Febuxostat | Tablet 80 mg | 50 | 56 | 5 |  |
| Felodipine | Tablet 2.5 mg (extended release) | 50 | 60 | 5 |  |
|  | Tablet 5 mg (extended release) | 50 | 60 | 5 |  |
|  | Tablet 10 mg (extended release) | 50 | 60 | 5 |  |
| Fenofibrate | Tablet 48 mg | 50 | 120 | 5 |  |
|  | Tablet 145 mg | 50 | 60 | 5 |  |
| Fluoxetine | Capsule 20 mg (as hydrochloride) | 50 | 56 | 2 |  |
|  | Tablet, dispersible, 20 mg (as hydrochloride) | 50 | 56 | 2 |  |
| Fluticasone furoate | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses | 50 | 2 | 5 |  |
| Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | 50 | 2 | 5 |  |
| Fluticasone furoate with vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | 50 | 2 | 5 |  |
| Fluticasone propionate | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses | 50 | 2 | 5 |  |
|  | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation) | 50 | 2 | 5 |  |
|  | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation) | 50 | 2 | 5 |  |
| Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | 50 | 2 | 5 |  |
|  | Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses | 50 | 2 | 5 |  |
|  | Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | 50 | 2 | 5 |  |
| Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | 50 | 2 | 5 |  |
|  | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | 50 | 2 | 5 |  |
|  | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | 50 | 2 | 5 |  |
|  | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | 50 | 2 | 5 |  |
| Fluvastatin | Tablet (prolonged release) 80 mg (as sodium) | 50 | 56 | 5 |  |
| Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | 50 | 60 | 2 |  |
|  | Tablet containing fluvoxamine maleate 50 mg | 50 | 60 | 2 |  |
| Formoterol | Capsule containing powder for oral inhalation containing formoterol fumarate dihydrate 12 micrograms (for use in Foradile Aerolizer) | 50 | 120 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | 50 | 2 | 5 |  |
|  | Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 6 micrograms per dose, 60 doses | 50 | 2 | 5 |  |
| Furosemide | Oral solution 10 mg per mL, 30 mL | 50 | 2 | 3 |  |
|  | Tablet 20 mg | 50 | 200 | 1 |  |
|  | Tablet 40 mg | 50 | 200 | 1 |  |
|  | Tablet 500 mg | 50 | 100 | 3 |  |
| Gemfibrozil | Tablet 600 mg | 50 | 120 | 5 |  |
| Glibenclamide | Tablet 5 mg | 50 | 200 | 5 |  |
| Gliclazide | Tablet 30 mg (modified release) | 50 | 200 | 5 |  |
|  | Tablet 60 mg (modified release) | 50 | 120 | 5 |  |
|  | Tablet 80 mg | 50 | 200 | 5 |  |
| Glimepiride | Tablet 1 mg | 50 | 60 | 5 |  |
|  | Tablet 2 mg | 50 | 60 | 5 |  |
|  | Tablet 3 mg | 50 | 60 | 5 |  |
|  | Tablet 4 mg | 50 | 60 | 5 |  |
| Glipizide | Tablet 5 mg | 50 | 200 | 5 |  |
| Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | 50 | 2 | 5 |  |
|  | Transdermal patch 18 mg | 50 | 60 | 5 |  |
|  | Transdermal patch 25 mg | 50 | 60 | 5 |  |
|  | Transdermal patch 36 mg | 50 | 60 | 5 |  |
|  | Transdermal patch 50 mg | 50 | 60 | 5 |  |
|  | Transdermal patch 54 mg | 50 | 60 | 5 |  |
| Glycopyrronium | Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler) | 50 | 60 | 5 |  |
| Hyaluronic acid | Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL | 50 | 2 | 5 |  |
|  | Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL | 50 | 2 | 5 |  |
| Hydrochlorothiazide | Tablet 25 mg | 50 | 200 | 1 |  |
| Hydrochlorothiazide with amiloride | Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg | 50 | 200 | 1 |  |
| Hydrocortisone | Tablet 4 mg | 50 | 100 | 4 |  |
|  | Tablet 20 mg | 50 | 120 | 4 |  |
| Hypromellose | 0.3% w/v eye drops, 10 mL (preservative free) | 50 | 2 | 5 |  |
|  | Eye drops 3 mg per mL, 10 mL | 50 | 2 | 5 |  |
|  | Eye drops 5 mg per mL, 15 mL | 50 | 2 | 5 |  |
| Hypromellose with dextran | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL | 50 | 2 | 5 |  |
| Indacaterol | Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler) | 50 | 60 | 5 |  |
|  | Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler) | 50 | 60 | 5 |  |
| Indacaterol with glycopyrronium | Capsule containing powder for oral inhalation indacaterol 110 micrograms (as maleate) with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler) | 50 | 60 | 5 |  |
| Indacaterol with glycopyrronium and mometasone | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 136 micrograms (for use in Breezhaler) | 50 | 60 | 5 |  |
|  | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 68 micrograms (for use in Breezhaler) | 50 | 60 | 5 |  |
| Indacaterol with mometasone | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 127.5 micrograms (for use in Breezhaler) | 50 | 60 | 5 |  |
|  | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 260 micrograms (for use in Breezhaler) | 50 | 60 | 5 |  |
|  | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 62.5 micrograms (for use in Breezhaler) | 50 | 60 | 5 |  |
| Indapamide | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | 50 | 180 | 1 |  |
|  | Tablet containing indapamide hemihydrate 2.5 mg | 50 | 180 | 1 |  |
| Irbesartan | Tablet 75 mg | 50 | 60 | 5 |  |
|  | Tablet 150 mg | 50 | 60 | 5 |  |
|  | Tablet 300 mg | 50 | 60 | 5 |  |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg‑12.5 mg | 50 | 60 | 5 |  |
|  | Tablet 300 mg‑12.5 mg | 50 | 60 | 5 |  |
|  | Tablet 300 mg‑25 mg | 50 | 60 | 5 |  |
| Isosorbide dinitrate | Tablet 5 mg (sublingual) | 50 | 400 | 2 |  |
| Isosorbide mononitrate | Tablet 60 mg (sustained release) | 50 | 60 | 5 |  |
|  | Tablet 120 mg (sustained release) | 50 | 60 | 5 |  |
| Labetalol | Tablet containing labetalol hydrochloride 100 mg | 50 | 200 | 5 |  |
| Lacosamide | Oral solution 10 mg per mL, 200 mL | 50 | 4 | 5 |  |
|  |  | 50 | 12 | 5 |  |
|  | Tablet 50 mg | 50 | 112 | 5 |  |
|  | Tablet 100 mg | 50 | 112 | 5 |  |
|  | Tablet 150 mg | 50 | 112 | 5 |  |
|  | Tablet 200 mg | 50 | 112 | 5 |  |
| Lamotrigine | Tablet 5 mg | 50 | 112 | 5 |  |
|  | Tablet 25 mg | 50 | 112 | 5 |  |
|  | Tablet 50 mg | 50 | 112 | 5 |  |
|  | Tablet 100 mg | 50 | 112 | 5 |  |
|  | Tablet 200 mg | 50 | 112 | 5 |  |
| Lansoprazole | Capsule 15 mg | 50 | 60 | 5 |  |
|  | Capsule 30 mg | 50 | 56 | 5 |  |
|  |  | 50 | 112 | 5 |  |
|  | Tablet 15 mg (orally disintegrating) | 50 | 56 | 5 |  |
|  | Tablet 30 mg (orally disintegrating) | 50 | 56 | 5 |  |
|  |  | 50 | 112 | 5 |  |
| Lanthanum | Tablet, chewable, 500 mg (as carbonate hydrate) | 50 | 180 | 5 |  |
|  | Tablet, chewable, 750 mg (as carbonate hydrate) | 50 | 180 | 5 |  |
|  | Tablet, chewable, 1000 mg (as carbonate hydrate) | 50 | 180 | 5 |  |
| Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | 50 | 2 | 5 |  |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | 50 | 2 | 5 |  |
| Leflunomide | Tablet 10 mg | 50 | 60 | 5 |  |
|  | Tablet 20 mg | 50 | 60 | 5 |  |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | 50 | 56 | 5 |  |
|  | Tablet containing lercanidipine hydrochloride 20 mg | 50 | 56 | 5 |  |
| Lercanidipine with enalapril | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg | 50 | 56 | 5 |  |
|  | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg | 50 | 56 | 5 |  |
| Letrozole | Tablet 2.5 mg | 50 | 60 | 5 |  |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL | 50 | 2 | 5 |  |
|  | Tablet 250 mg | 50 | 120 | 5 |  |
|  | Tablet 500 mg | 50 | 120 | 5 |  |
|  | Tablet 1 g | 50 | 120 | 5 |  |
| Levodopa with benserazide | Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | 50 | 200 | 5 |  |
|  | Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) (sustained release) | 50 | 200 | 5 |  |
|  | Capsule containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride) | 50 | 200 | 5 |  |
|  | Capsule containing levodopa 200 mg with 50 mg benserazide (as hydrochloride) | 50 | 200 | 5 |  |
|  | Dispersible tablet containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride) | 50 | 200 | 5 |  |
|  | Dispersible tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | 50 | 200 | 5 |  |
|  | Tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | 50 | 200 | 5 |  |
|  | Tablet containing levodopa 200 mg with 50 mg benserazide (as hydrochloride) | 50 | 200 | 5 |  |
| Levodopa with carbidopa | Tablet (modified release) 200 mg-50 mg (as monohydrate) | 50 | 200 | 5 |  |
|  | Tablet 100 mg-25 mg (as monohydrate) | 50 | 200 | 5 |  |
|  | Tablet 250 mg-25 mg (as monohydrate) | 50 | 200 | 5 |  |
| Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | 50 | 400 | 4 |  |
|  | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | 50 | 400 | 4 |  |
|  | Tablet 100 mg-25 mg (as monohydrate)-200 mg | 50 | 400 | 4 |  |
|  | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | 50 | 400 | 4 |  |
|  | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | 50 | 400 | 4 |  |
|  | Tablet 200 mg-50 mg (as monohydrate)-200 mg | 50 | 400 | 4 |  |
| Linagliptin | Tablet 5 mg | 50 | 60 | 5 |  |
| Linagliptin with metformin | Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride | 50 | 120 | 5 |  |
|  | Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride | 50 | 120 | 5 |  |
|  | Tablet containing 2.5 mg linagliptin with 1000 mg metformin hydrochloride | 50 | 120 | 5 |  |
| Liothyronine | Tablet containing liothyronine sodium 20 micrograms | 50 | 200 | 2 |  |
| Lisinopril | Tablet 5 mg | 50 | 60 | 5 |  |
|  | Tablet 10 mg | 50 | 60 | 5 |  |
|  | Tablet 20 mg | 50 | 60 | 5 |  |
| Macrogol 3350 | Powder for oral solution 510 g | 50 | 2 | 5 |  |
|  | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | 50 | 2 | 5 |  |
| Medroxyprogesterone | Tablet containing medroxyprogesterone acetate 5 mg | 50 | 112 | 2 |  |
|  | Tablet containing medroxyprogesterone acetate 10 mg | 50 | 60 | 2 |  |
|  |  | 50 | 200 | 2 |  |
|  | Tablet containing medroxyprogesterone acetate 100 mg | 50 | 200 | 2 |  |
|  | Tablet containing medroxyprogesterone acetate 200 mg | 50 | 120 | 2 |  |
|  | Tablet containing medroxyprogesterone acetate 250 mg | 50 | 120 | 2 |  |
| Mesalazine | Enemas 1 g in 100 mL, 7 | 50 | 8 | 5 |  |
|  | Enemas 2 g in 60 mL, 7 | 50 | 8 | 5 |  |
|  | Enemas 4 g in 60 mL, 7 | 50 | 8 | 5 |  |
|  | Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g | 50 | 8 | 5 |  |
|  | Sachet containing granules, 500 mg per sachet | 50 | 400 | 5 |  |
|  | Sachet containing granules, 1 g per sachet | 50 | 200 | 5 |  |
|  | Sachet containing granules, 1.5 g per sachet | 50 | 120 | 5 |  |
|  | Sachet containing granules, 3 g per sachet | 50 | 60 | 5 |  |
|  | Sachet containing prolonged release granules, 1 g per sachet | 50 | 200 | 5 |  |
|  | Sachet containing prolonged release granules, 2 g per sachet | 50 | 120 | 5 |  |
|  | Sachet containing prolonged release granules, 4 g per sachet | 50 | 60 | 5 |  |
|  | Suppository (moulded) 1 g | 50 | 60 | 5 |  |
|  | Suppository 1 g | 50 | 56 | 5 |  |
|  | Tablet 250 mg (enteric coated) | 50 | 200 | 5 |  |
|  | Tablet 500 mg (enteric coated) | 50 | 400 | 5 |  |
|  | Tablet 500 mg (prolonged release) | 50 | 400 | 5 |  |
|  | Tablet 800 mg (enteric coated) | 50 | 180 | 5 |  |
|  | Tablet 1 g (enteric coated) | 50 | 240 | 5 |  |
|  | Tablet 1 g (prolonged release) | 50 | 240 | 5 |  |
|  | Tablet 1.2 g (prolonged release) | 50 | 240 | 5 |  |
|  | Tablet 1.6 g (enteric coated) | 50 | 240 | 4 |  |
| Metformin | Tablet containing metformin hydrochloride 500 mg | 50 | 200 | 5 |  |
|  | Tablet containing metformin hydrochloride 850 mg | 50 | 120 | 5 |  |
|  | Tablet containing metformin hydrochloride 1 g | 50 | 180 | 5 |  |
|  | Tablet (extended release) containing metformin hydrochloride 500 mg | 50 | 240 | 5 |  |
|  | Tablet (extended release) containing metformin hydrochloride 1 g | 50 | 120 | 5 |  |
| Methenamine | Tablet containing methenamine hippurate 1 g | 50 | 200 | 5 |  |
| Methotrexate | Injection 50 mg in 2 mL vial | 50 | 10 | 5 |  |
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | 50 | 200 | 5 |  |
|  | Tablet containing metoprolol tartrate 100 mg | 50 | 120 | 5 |  |
| Metoprolol succinate | Tablet 47.5 mg (controlled release) | 50 | 60 | 5 |  |
|  | Tablet 95 mg (controlled release) | 50 | 60 | 5 |  |
|  | Tablet 190 mg (controlled release) | 50 | 60 | 5 |  |
| Mianserin | Tablet containing mianserin hydrochloride 10 mg | 50 | 100 | 2 |  |
|  | Tablet containing mianserin hydrochloride 20 mg | 50 | 100 | 2 |  |
| Minocycline | Tablet 50 mg (as hydrochloride) | 50 | 120 | 2 |  |
| Minoxidil | Tablet 10 mg | 50 | 200 | 5 |  |
| Mirtazapine | Tablet 15 mg | 50 | 60 | 2 |  |
|  | Tablet 15 mg (orally disintegrating) | 50 | 60 | 2 |  |
|  | Tablet 30 mg | 50 | 60 | 2 |  |
|  | Tablet 30 mg (orally disintegrating) | 50 | 60 | 2 |  |
|  | Tablet 45 mg | 50 | 60 | 2 |  |
|  | Tablet 45 mg (orally disintegrating) | 50 | 60 | 2 |  |
| Moclobemide | Tablet 150 mg | 50 | 120 | 2 |  |
|  | Tablet 300 mg | 50 | 120 | 2 |  |
| Montelukast | Tablet, chewable, 4 mg (as sodium) | 50 | 56 | 5 |  |
|  | Tablet, chewable, 5 mg (as sodium) | 50 | 56 | 5 |  |
| Moxonidine | Tablet 200 micrograms | 50 | 60 | 5 |  |
|  | Tablet 400 micrograms | 50 | 60 | 5 |  |
| Mycophenolic acid | Capsule containing mycophenolate mofetil 250 mg | 50 | 600 | 5 |  |
|  | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL | 50 | 2 | 5 |  |
|  | Tablet containing mycophenolate mofetil 500 mg | 50 | 300 | 5 |  |
|  | Tablet (enteric coated) containing mycophenolate sodium equivalent to 180 mg mycophenolic acid | 50 | 240 | 5 |  |
|  | Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid | 50 | 240 | 5 |  |
| Nebivolol | Tablet 1.25 mg (as hydrochloride) | 50 | 112 | 5 |  |
|  | Tablet 5 mg (as hydrochloride) | 50 | 56 | 5 |  |
|  | Tablet 10 mg (as hydrochloride) | 50 | 56 | 5 |  |
| Nicorandil | Tablets 10 mg, 60 | 50 | 2 | 5 |  |
|  | Tablets 20 mg, 60 | 50 | 2 | 5 |  |
| Nifedipine | Tablet 30 mg (controlled release) | 50 | 60 | 5 |  |
|  | Tablet 60 mg (controlled release) | 50 | 60 | 5 |  |
| Nizatidine | Capsule 150 mg | 50 | 120 | 5 |  |
|  | Capsule 300 mg | 50 | 60 | 5 |  |
| Norethisterone | Tablet 5 mg | 50 | 60 | 2 |  |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | 50 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg | 50 | 60 | 5 |  |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | 50 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | 50 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | 50 | 60 | 5 |  |
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | 50 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | 50 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | 50 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | 50 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | 50 | 60 | 5 |  |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | 50 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | 50 | 60 | 5 |  |
|  | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | 50 | 60 | 5 |  |
| Omeprazole | Capsule 20 mg | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
|  | Tablet 10 mg (as magnesium) | 50 | 60 | 5 |  |
|  | Tablet 20 mg | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
|  | Tablet 20 mg (as magnesium) | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
| Oxcarbazepine | Oral suspension 60 mg per mL, 250 mL | 50 | 4 | 5 |  |
|  | Tablet 150 mg | 50 | 200 | 5 |  |
|  | Tablet 300 mg | 50 | 200 | 5 |  |
|  | Tablet 600 mg | 50 | 200 | 5 |  |
| Oxybutynin | Tablet containing oxybutynin hydrochloride 5 mg | 50 | 200 | 5 |  |
|  | Transdermal patches 36 mg, 8 | 50 | 2 | 5 |  |
| Pancreatic extract | Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity | 50 | 1000 | 10 |  |
|  | Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity | 50 | 400 | 10 |  |
|  | Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity | 50 | 400 | 10 |  |
|  | Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g | 50 | 6 | 10 |  |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
|  | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | 50 | 60 | 5 |  |
|  | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
| Paraffin | Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer-188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free) | 50 | 2 | 5 |  |
|  | Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | 50 | 4 | 5 |  |
|  | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | 50 | 2 | 5 |  |
| Paroxetine | Tablet 20 mg (as hydrochloride) | 50 | 60 | 2 |  |
| Penicillamine | Tablet 125 mg | 50 | 200 | 1 |  |
|  | Tablet 250 mg | 50 | 200 | 1 |  |
| Perampanel | Tablet 4 mg (as hemisesquihydrate) | 50 | 56 | 5 |  |
|  | Tablet 6 mg (as hemisesquihydrate) | 50 | 56 | 5 |  |
|  | Tablet 8 mg (as hemisesquihydrate) | 50 | 56 | 5 |  |
|  | Tablet 10 mg (as hemisesquihydrate) | 50 | 56 | 5 |  |
|  | Tablet 12 mg (as hemisesquihydrate) | 50 | 56 | 5 |  |
| Perfluorohexyloctane | Eye drops, 3 mL | 50 | 2 | 5 |  |
| Perindopril | Tablet containing perindopril arginine 2.5 mg | 50 | 60 | 5 |  |
|  | Tablet containing perindopril arginine 5 mg | 50 | 60 | 5 |  |
|  | Tablet containing perindopril arginine 10 mg | 50 | 60 | 5 |  |
|  | Tablet containing perindopril erbumine 2 mg | 50 | 60 | 5 |  |
|  | Tablet containing perindopril erbumine 4 mg | 50 | 60 | 5 |  |
|  | Tablet containing perindopril erbumine 8 mg | 50 | 60 | 5 |  |
| Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) | 50 | 60 | 5 |  |
|  | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | 50 | 60 | 5 |  |
|  | Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) | 50 | 60 | 5 |  |
|  | Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) | 50 | 60 | 5 |  |
| Perindopril with indapamide | Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg | 50 | 60 | 5 |  |
|  | Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg | 50 | 60 | 5 |  |
|  | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | 50 | 60 | 5 |  |
| Phenoxymethylpenicillin | Capsule 250 mg phenoxymethylpenicillin (as potassium) | 50 | 100 | 5 |  |
|  | Tablet 250 mg phenoxymethylpenicillin (as potassium) | 50 | 100 | 5 |  |
| Phenytoin | Capsule containing phenytoin sodium 30 mg | 50 | 400 | 2 |  |
|  | Capsule containing phenytoin sodium 100 mg | 50 | 400 | 2 |  |
|  | Oral suspension 30 mg per 5 mL, 500 mL | 50 | 2 | 3 |  |
|  | Tablet 50 mg | 50 | 400 | 2 |  |
| Pilocarpine | Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL | 50 | 2 | 5 |  |
|  | Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL | 50 | 2 | 5 |  |
|  | Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL | 50 | 2 | 5 |  |
| Pioglitazone | Tablet 15 mg (as hydrochloride) | 50 | 56 | 5 |  |
|  | Tablet 30 mg (as hydrochloride) | 50 | 56 | 5 |  |
|  | Tablet 45 mg (as hydrochloride) | 50 | 56 | 5 |  |
| Pizotifen | Tablet 500 micrograms (as malate) | 50 | 200 | 2 |  |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, 15 mL | 50 | 2 | 5 |  |
|  | Eye drops 4 mg-3 mg per mL, single dose units 0.8 mL, 30 | 50 | 4 | 5 |  |
| Potassium chloride | Tablet 600 mg (sustained release) | 50 | 400 | 1 |  |
| Potassium chloride with potassium bicarbonate | Tablet, effervescent, 14 mmol potassium and 8 mmol chloride | 50 | 120 | 1 |  |
| Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | 50 | 60 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | 50 | 60 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | 50 | 60 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | 50 | 60 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms | 50 | 60 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | 50 | 60 | 5 |  |
|  | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms | 50 | 60 | 5 |  |
|  | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | 50 | 200 | 5 |  |
|  | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | 50 | 200 | 5 |  |
| Pravastatin | Tablet containing pravastatin sodium 10 mg | 50 | 60 | 5 |  |
|  | Tablet containing pravastatin sodium 20 mg | 50 | 60 | 5 |  |
|  | Tablet containing pravastatin sodium 40 mg | 50 | 60 | 5 |  |
|  | Tablet containing pravastatin sodium 80 mg | 50 | 60 | 5 |  |
| Prazosin | Capsule 1 mg (as hydrochloride) (S19A) | 50 | 200 | 5 |  |
|  | Tablet 1 mg (as hydrochloride) | 50 | 200 | 5 |  |
|  | Tablet 2 mg (as hydrochloride) | 50 | 200 | 5 |  |
|  | Tablet 5 mg (as hydrochloride) | 50 | 200 | 5 |  |
| Prednisolone | Oral solution 5 mg (as sodium phosphate) per mL, 30 mL | 50 | 2 | 5 |  |
|  | Tablet 1 mg | 50 | 200 | 4 |  |
|  | Tablet 5 mg | 50 | 120 | 4 |  |
| Prednisone | Tablet 1 mg | 50 | 200 | 4 |  |
|  | Tablet 5 mg | 50 | 120 | 4 |  |
| Probenecid | Tablet 500 mg | 50 | 200 | 5 |  |
| Progesterone | Capsule 100 mg | 50 | 60 | 5 |  |
| Progesterone and estradiol | Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses | 50 | 2 | 5 |  |
| Propantheline | Tablet containing propantheline bromide 15 mg | 50 | 400 | 5 |  |
| Propranolol | Tablet containing propranolol hydrochloride 10 mg | 50 | 200 | 5 |  |
|  | Tablet containing propranolol hydrochloride 40 mg | 50 | 200 | 5 |  |
| Propylthiouracil | Tablet 50 mg | 50 | 400 | 2 |  |
| Pyridostigmine | Tablet containing pyridostigmine bromide 10 mg | 50 | 200 | 5 |  |
|  | Tablet containing pyridostigmine bromide 180 mg (modified release) | 50 | 200 | 5 |  |
|  | Tablet containing pyridostigmine bromide 60 mg | 50 | 300 | 5 |  |
| Quinagolide | Tablet 75 micrograms (as hydrochloride) | 50 | 60 | 5 |  |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | 50 | 56 | 5 |  |
|  | Tablet containing rabeprazole sodium 20 mg (enteric coated) | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | 50 | 56 | 5 |  |
| Ramipril | Capsule 1.25 mg | 50 | 60 | 5 |  |
|  | Capsule 2.5 mg | 50 | 60 | 5 |  |
|  | Capsule 5 mg | 50 | 60 | 5 |  |
|  | Capsule 10 mg | 50 | 60 | 5 |  |
|  | Tablet 1.25 mg | 50 | 60 | 5 |  |
|  | Tablet 2.5 mg | 50 | 60 | 5 |  |
|  | Tablet 5 mg | 50 | 60 | 5 |  |
|  | Tablet 10 mg | 50 | 60 | 5 |  |
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | 50 | 60 | 5 |  |
|  | Tablet 5 mg‑5 mg (modified release) | 50 | 60 | 5 |  |
| Rasagiline | Tablet 1 mg (as mesilate) | 50 | 60 | 5 |  |
| Reboxetine | Tablet 4 mg (as mesilate) | 50 | 120 | 2 |  |
| Riluzole | Oral suspension 50 mg per 10 mL, 300 mL | 50 | 4 | 5 |  |
|  | Tablet 50 mg | 50 | 112 | 5 |  |
| Risedronic acid | Tablet containing risedronate sodium 5 mg | 50 | 56 | 5 |  |
|  | Tablet containing risedronate sodium 35 mg | 50 | 8 | 5 |  |
|  | Tablet containing risedronate sodium 150 mg | 50 | 2 | 5 |  |
|  | Tablet (enteric coated) containing risedronate sodium 35 mg | 50 | 8 | 5 |  |
| Rivaroxaban | Tablet 2.5 mg | 50 | 120 | 5 |  |
|  | Tablet 10 mg | 50 | 60 | 5 |  |
|  | Tablet 15 mg | 50 | 56 | 5 |  |
|  | Tablet 20 mg | 50 | 56 | 5 |  |
| Rosuvastatin | Tablet 5 mg (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 10 mg (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 20 mg (as calcium) | 50 | 60 | 5 |  |
|  | Tablet 40 mg (as calcium) | 50 | 60 | 5 |  |
| Rotigotine | Transdermal patch 4.5 mg | 50 | 56 | 5 |  |
|  | Transdermal patch 9 mg | 50 | 56 | 5 |  |
|  | Transdermal patch 13.5 mg | 50 | 56 | 5 |  |
|  | Transdermal patch 18 mg | 50 | 56 | 5 |  |
| Sacubitril with valsartan | Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg | 50 | 112 | 5 |  |
|  | Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg | 50 | 112 | 5 |  |
|  | Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg | 50 | 112 | 5 |  |
| Safinamide | Tablet 50 mg | 50 | 60 | 5 |  |
|  | Tablet 100 mg | 50 | 60 | 5 |  |
| Salmeterol | Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses | 50 | 2 | 5 |  |
| Saxagliptin | Tablet 2.5 mg (as hydrochloride) | 50 | 56 | 5 |  |
|  | Tablet 5 mg (as hydrochloride) | 50 | 56 | 5 |  |
| Saxagliptin with dapagliflozin | Tablet containing saxagliptin 5 mg with dapaglifozin 10 mg | 50 | 56 | 5 |  |
| Saxagliptin with metformin | Tablet (modified release) containing 2.5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | 50 | 112 | 5 |  |
|  | Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 500 mg metformin hydrochloride | 50 | 56 | 5 |  |
|  | Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | 50 | 56 | 5 |  |
| Selegiline | Tablet containing selegiline hydrochloride 5 mg | 50 | 200 | 5 |  |
| Sertraline | Tablet 50 mg (as hydrochloride) | 50 | 60 | 2 |  |
|  | Tablet 100 mg (as hydrochloride) | 50 | 60 | 2 |  |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | 50 | 360 | 5 |  |
|  | Tablet containing sevelamer hydrochloride 800 mg | 50 | 360 | 5 |  |
| Simvastatin | Tablet 5 mg | 50 | 60 | 5 |  |
|  | Tablet 10 mg | 50 | 60 | 5 |  |
|  | Tablet 20 mg | 50 | 60 | 5 |  |
|  | Tablet 40 mg | 50 | 60 | 5 |  |
|  | Tablet 80 mg | 50 | 60 | 5 |  |
| Sirolimus | Oral solution 1 mg per mL, 60 mL | 50 | 2 | 3 |  |
|  | Tablet 0.5 mg | 50 | 200 | 3 |  |
|  | Tablet 1 mg | 50 | 200 | 3 |  |
|  | Tablet 2 mg | 50 | 200 | 3 |  |
| Sitagliptin | Tablet 25 mg | 50 | 56 | 5 |  |
|  | Tablet 50 mg | 50 | 56 | 5 |  |
|  | Tablet 100 mg | 50 | 56 | 5 |  |
| Sitagliptin with metformin | Tablet containing 50 mg sitagliptin with 500 mg metformin hydrochloride | 50 | 112 | 5 |  |
|  | Tablet containing 50 mg sitagliptin with 850 mg metformin hydrochloride | 50 | 112 | 5 |  |
|  | Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | 50 | 112 | 5 |  |
|  | Tablet containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | 50 | 112 | 5 |  |
|  | Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride | 50 | 56 | 5 |  |
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | 50 | 200 | 5 |  |
| Sodium bicarbonate | Capsule 840 mg | 50 | 200 | 2 |  |
| Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Enemas 3.125 g-450 mg-45 mg in 5 mL, 12 | 50 | 4 | 2 |  |
| Soy lecithin | Eye spray 10 mg per mL, 10 mL | 50 | 4 | 5 |  |
| Spironolactone | Tablet 25 mg | 50 | 200 | 5 |  |
|  | Tablet 100 mg | 50 | 200 | 5 |  |
| Sucroferric oxyhydroxide | Tablet, chewable, 2.5 g (equivalent to 500 mg iron) | 50 | 180 | 5 |  |
| Sulfasalazine | Tablet 500 mg | 50 | 400 | 5 |  |
|  | Tablet 500 mg (enteric coated) | 50 | 400 | 5 |  |
| Sulthiame | Tablet 50 mg | 50 | 400 | 2 |  |
|  | Tablet 200 mg | 50 | 400 | 2 |  |
| Tacrolimus | Capsule 0.5 mg | 50 | 200 | 3 |  |
|  | Capsule 0.5 mg (once daily prolonged release) | 50 | 60 | 3 |  |
|  | Capsule 0.75 mg | 50 | 200 | 3 |  |
|  | Capsule 1 mg | 50 | 200 | 3 |  |
|  | Capsule 1 mg (once daily prolonged release) | 50 | 120 | 3 |  |
|  | Capsule 2 mg | 50 | 200 | 3 |  |
|  | Capsule 3 mg (once daily prolonged release) | 50 | 100 | 2 |  |
|  | Capsule 5 mg | 50 | 100 | 3 |  |
|  | Capsule 5 mg (once daily prolonged release) | 50 | 60 | 3 |  |
| Tamoxifen | Tablet 20 mg (as citrate) | 50 | 60 | 5 |  |
|  |  | 50 | 120 | 5 |  |
| Telmisartan | Tablet 40 mg | 50 | 56 | 5 |  |
|  | Tablet 80 mg | 50 | 56 | 5 |  |
| Telmisartan with amlodipine | Tablet 40 mg‑5 mg (as besilate) | 50 | 56 | 5 |  |
|  | Tablet 40 mg‑10 mg (as besilate) | 50 | 56 | 5 |  |
|  | Tablet 80 mg‑5 mg (as besilate) | 50 | 56 | 5 |  |
|  | Tablet 80 mg‑10 mg (as besilate) | 50 | 56 | 5 |  |
| Telmisartan with hydrochlorothiazide | Tablet 40 mg‑12.5 mg | 50 | 56 | 5 |  |
|  | Tablet 80 mg‑12.5 mg | 50 | 56 | 5 |  |
|  | Tablet 80 mg‑25 mg | 50 | 56 | 5 |  |
| Teriparatide | Injection 250 micrograms per mL, 2.4 mL in multi‑dose pre‑filled pen | 50 | 2 | 2 |  |
| Testosterone | Transdermal cream 50 mg per mL, 50 mL | 50 | 2 | 1 |  |
|  | Transdermal gel 50 mg in 5 g sachet, 30 | 50 | 2 | 5 |  |
|  | Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2 | 50 | 2 | 4 |  |
|  | Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses | 50 | 2 | 5 |  |
| Tetrabenazine | Tablet 25 mg | 50 | 224 | 5 |  |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | 50 | 200 | 2 |  |
| Tiagabine | Tablet 5 mg (as hydrochloride) | 50 | 200 | 5 |  |
|  | Tablet 10 mg (as hydrochloride) | 50 | 200 | 5 |  |
|  | Tablet 15 mg (as hydrochloride) | 50 | 200 | 5 |  |
| Ticagrelor | Tablet 90 mg | 50 | 112 | 5 |  |
| Tiotropium | Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device) | 50 | 60 | 5 |  |
|  | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler) | 50 | 60 | 5 |  |
|  | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in LupinHaler) | 50 | 60 | 5 |  |
|  | Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations) | 50 | 2 | 5 |  |
|  | Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations), pack of 2 | 50 | 1 | 5 |  |
| Tiotropium with olodaterol | Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses | 50 | 2 | 5 |  |
|  | Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses, pack of 2 | 50 | 1 | 5 |  |
| Tobramycin | Capsule containing powder for oral inhalation 28 mg (for use in podhaler) | 50 | 448 | 2 |  |
|  | Solution for inhalation 300 mg in 5 mL | 50 | 112 | 2 |  |
| Topiramate | Capsule 15 mg | 50 | 120 | 5 |  |
|  | Capsule 25 mg | 50 | 120 | 5 |  |
|  | Capsule 50 mg | 50 | 120 | 5 |  |
|  | Tablet 25 mg | 50 | 120 | 5 |  |
|  | Tablet 50 mg | 50 | 120 | 5 |  |
|  | Tablet 100 mg | 50 | 120 | 5 |  |
|  | Tablet 200 mg | 50 | 120 | 5 |  |
| Toremifene | Tablet 60 mg (as citrate) | 50 | 60 | 5 |  |
| Trandolapril | Capsule 500 micrograms | 50 | 56 | 5 |  |
|  | Capsule 1 mg | 50 | 56 | 5 |  |
|  | Capsule 2 mg | 50 | 56 | 5 |  |
|  | Capsule 4 mg | 50 | 56 | 5 |  |
| Trandolapril with verapamil | Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) | 50 | 56 | 5 |  |
|  | Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) | 50 | 56 | 5 |  |
| Tranylcypromine | Tablet 10 mg (as sulfate) | 50 | 100 | 1 |  |
| Travoprost | Eye drops 40 micrograms per mL, 2.5 mL | 50 | 2 | 5 |  |
| Travoprost with timolol | Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | 50 | 2 | 5 |  |
| Umeclidinium | Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses | 50 | 2 | 5 |  |
| Umeclidinium with vilanterol | Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | 50 | 2 | 5 |  |
| Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | 50 | 4 | 2 |  |
|  | Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL | 50 | 4 | 2 |  |
|  | Tablet, crushable, containing sodium valproate 100 mg | 50 | 400 | 2 |  |
|  | Tablet (enteric coated) containing sodium valproate 200 mg | 50 | 400 | 2 |  |
|  | Tablet (enteric coated) containing sodium valproate 500 mg | 50 | 400 | 2 |  |
| Valsartan | Tablet 80 mg | 50 | 56 | 5 |  |
|  | Tablet 160 mg | 50 | 56 | 5 |  |
|  | Tablet 320 mg | 50 | 56 | 5 |  |
| Valsartan with hydrochlorothiazide | Tablet 80 mg‑12.5 mg | 50 | 56 | 5 |  |
|  | Tablet 160 mg‑12.5 mg | 50 | 56 | 5 |  |
|  | Tablet 160 mg‑25 mg | 50 | 56 | 5 |  |
|  | Tablet 320 mg‑12.5 mg | 50 | 56 | 5 |  |
|  | Tablet 320 mg‑25 mg | 50 | 56 | 5 |  |
| Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | 50 | 56 | 2 |  |
|  | Capsule (modified release) 150 mg (as hydrochloride) | 50 | 56 | 2 |  |
| Verapamil | Tablet containing verapamil hydrochloride 80 mg | 50 | 200 | 5 |  |
|  | Tablet containing verapamil hydrochloride 180 mg (sustained release) | 50 | 60 | 5 |  |
|  | Tablet containing verapamil hydrochloride 240 mg (sustained release) | 50 | 60 | 5 |  |
| Vigabatrin | Oral powder, sachet 500 mg | 50 | 120 | 5 |  |
|  | Tablet 500 mg | 50 | 200 | 5 |  |
| Vildagliptin | Tablet 50 mg | 50 | 120 | 5 |  |
| Vildagliptin with metformin | Tablet containing 50 mg vildagliptin with 500 mg metformin hydrochloride | 50 | 120 | 5 |  |
|  | Tablet containing 50 mg vildagliptin with 850 mg metformin hydrochloride | 50 | 120 | 5 |  |
|  | Tablet containing 50 mg vildagliptin with 1000 mg metformin hydrochloride | 50 | 120 | 5 |  |
| Zonisamide | Capsule 25 mg | 50 | 112 | 5 |  |
|  | Capsule 50 mg | 50 | 112 | 5 |  |
|  | Capsule 100 mg | 50 | 224 | 5 |  |

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Editorial changes**

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = *Legislation Act 2003* | Sch = Schedule(s) |
| LIA = *Legislative Instruments Act 2003* | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |

Endnote 3—Legislation history

| Name | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| PB 120 of 2015 | 24 Dec 2015 (F2015L02129) | 1 Jan 2016 (s 2) |  |
| PB 4 of 2016 | 1 Feb 2016 (F2016L00074) | 1 Feb 2016 (s 2) | — |
| PB 12 of 2016 | 1 Mar 2016 (F2016L00200) | 1 Mar 2016 (s 2) | — |
| PB 21 of 2016 | 1 Apr 2016 (F2016L00482) | 1 Apr 2016 (s 2) | — |
| PB 32 of 2016 | 29 Apr 2016 (F2016L00601) | 1 May 2016 (s 2) | — |
| PB 54 of 2016 | 22 June 2016 (F2016L01055) | 1 July 2016 (s 2) | — |
| PB 66 of 2016 | 19 July 2016 (F2016L01197) | 1 Aug 2016 (s 2) | — |
| PB 75 of 2016 | 18 Aug 2016 (F2016L01297) | 1 Sept 2016 (s 2) | — |
| PB 83 of 2016 | 30 Sept 2016 (F2016L01561) | 1 Oct 2016 (s 2) | — |
| PB 92 of 2016 | 31 Oct 2016 (F2016L01679) | 1 Nov 2016 (s 2) | — |
| PB 99 of 2016 | 30 Nov 2016 (F2016L01834) | 1 Dec 2016 (s 2) | — |
| PB 111 of 2016 | 22 Dec 2016 (F2016L02025) | 1 Jan 2017 (s 2) | — |
| PB 4 of 2017 | 25 Jan 2017 (F2017L00068) | 1 Feb 2017 (s 2) | — |
| PB 19 of 2017 | 30 Mar 2017 (F2017L00358) | 1 Apr 2017 (s 2) | — |
| PB 29 of 2017 | 28 Apr 2017 (F2017L00485) | 1 May 2017 (s 2) | — |
| PB 38 of 2017 | 31 May 2017 (F2017L00628) | 1 June 2017 (s 2) | — |
| PB 46 of 2017 | 28 June 2017 (F2017L00774) | 1 July 2017 (s 2) | — |
| PB 65 of 2017 | 30 Aug 2017 (F2017L01105) | 1 Sept 2017 (s 2) | — |
| PB 74 of 2017 | 27 Sept 2017 (F2017L01278) | 1 Oct 2017 (s 2) | — |
| PB 87 of 2017 | 24 Oct 2017 (F2017L01387) | 1 Nov 2017 (s 2) | — |
| PB 94 of 2017 | 29 Nov 2017 (F2017L01541) | 1 Dec 2017 (s 2) | — |
| PB 103 of 2017 | 18 Dec 2017 (F2017L01629) | 1 Jan 2018 (s 2) | — |
| PB 4 of 2018 | 24 Jan 2018 (F2018L00054) | 1 Feb 2018 (s 2) | — |
| PB 15 of 2018 | 28 Feb 2018 (F2018L00164) | 1 Mar 2018 (s 2) | — |
| PB 21 of 2018 | 28 Mar 2018 (F2018L00422) | 1 Apr 2018 (s 2) | — |
| PB 32 of 2018 | 30 Apr 2018 (F2018L00546) | 1 May 2018 (s 2) | — |
| PB 39 of 2018 | 31 May 2018 (F2018L00688) | 1 June 2018 (s 2) | — |
| PB 52 of 2018 | 29 June 2018 (F2018L00942) | 1 July 2018 (s 2) | — |
| PB 65 of 2018 | 1 Aug 2018 (F2018L01075) | 1 Aug 2018 (s 2) | — |
| PB 76 of 2018 | 30 Aug 2018 (F2018L01230) | 1 Sept 2018 (s 2) | — |
| PB 93 of 2018 | 29 Oct 2018 (F2018L01486) | 1 Nov 2018 (s 2) | — |
| PB 100 of 2018 | 29 Nov 2018 (F2018L01626) | 1 Dec 2018 (s 2) | — |
| PB 2 of 2019 | 31 Jan 2019 (F2019L00076) | 1 Feb 2019 (s 2) | — |
| PB 12 of 2019 | 27 Feb 2019 (F2019L00208) | 1 Mar 2019 (s 2) | — |
| PB 19 of 2019 | 28 Mar 2019 (F2019L00454) | 1 Apr 2019 (s 2) | — |
| PB 30 of 2019 | 30 Apr 2019 (F2019L00654) | 1 May 2019 (s 2) | — |
| PB 38 of 2019 | 30 May 2019 (F2019L00698) | 1 June 2019 (s 2) | — |
| PB 47 of 2019 | 28 June 2019 (F2019L00908) | 1 July 2019 (s 2) | — |
| PB 60 of 2019 | 29 July 2019 (F2019L01009) | 1 Aug 2019 (s 2) | — |
| PB 68 of 2019 | 30 Aug 2019 (F2019L01128) | 1 Sept 2019 (s 2) | — |
| PB 77 of 2019 | 30 Sept 2019 (F2019L01297) | 1 Oct 2019 (s 2) | — |
| PB 86 of 2019 | 31 Oct 2019 (F2019L01389) | 1 Nov 2019 (s 2) | — |
| PB 94 of 2019 | 28 Nov 2019 (F2019L01522) | 1 Dec 2019 (s 2) | — |
| PB 105 of 2019 | 23 Dec 2019 (F2019L01694) | 1 Jan 2020 (s 2) | — |
| PB 3 of 2020 | 30 Jan 2020 (F2020L00065) | 1 Feb 2020 (s 2) | — |
| PB 15 of 2020 | 28 Feb 2020 (F2020L00178) | 1 Mar 2020 (s 2) | — |
| PB 21 of 2020 | 31 Mar 2020 (F2020L00367) | 1 Apr 2020 (s 2) | — |
| PB 34 of 2020 | 30 Apr 2020 (F2020L00524) | 30 Apr 2020 (s 2) | — |
| PB 56 of 2020 | 30 June 2020 (F2020L00850) | 1 July 2020 (s 2) | — |
| PB 68 of 2020 | 31 July 2020 (F2020L00967) | 1 Aug 2020 (s 2) | — |
| PB 79 of 2020 | 27 Aug 2020 (F2020L01073) | 1 Sept 2020 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 8) (PB 90 of 2020) | 30 Sept 2020 (F2020L01265) | 1 Oct 2020 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 9)( PB 103 of 2020) | 30 Oct 2020 (F2020L01357) | 1 Nov 2020 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 10) (PB 112 of 2020) | 27 Nov 2020 (F2020L01492) | 1 Dec 2020 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 11) (PB 125 of 2020) | 22 Dec 2020 (F2020L01681) | 1 Jan 2021 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 1) (PB 2 of 2021) | 28 Jan 2021 (F2021L00075) | 1 Feb 2021 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 2) (PB 14 of 2021) | 28 Feb 2021 (F2021L00165) | 1 Mar 2021 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 3) (PB 23 of 2021) | 31 Mar 2021 (F2021L00395) | 1 Apr 2021 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No.4) (PB 39 of 2021) | 30 Apr 2021 (F2021L00518) | 1 May 2021 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 5) (PB 47 of 2021) | 28 May 2021 (F2021L00655) | 1 June 2021 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 6) (PB 61 of 2021) | 29 June 2021 (F2021L00893) | 1 July 2021 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 7) (PB 75 of 2021) | 31 July 2021 (F2021L01054) | 1 Aug 2021 (s 2) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 8) (PB 88 of 2021) | 31 Aug 2021 (F2021L01219) | 1 Sept 2021 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 9) (PB 98 of 2021) | 30 Sept 2021 (F2021L01358) | 1 Oct 2021 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 10) (PB 110 of 2021) | 31 Oct 2021 (F2021L01487) | 1 Nov 2021 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 11) (PB 119 of 2021) | 30 Nov 2021 (F2021L01651) | 1 Dec 2021 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 12) (PB 129 of 2021) | 24 Dec 2021 (F2021L01895) | 1 Jan 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 1) (PB 2 of 2022) | 31 Jan 2022 (F2022L00090) | 1 Feb 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 2) (PB 12 of 2022) | 28 Feb 2022 (F2022L00202) | 1 Mar 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 3) (PB 24 of 2022) | 31 Mar 2022 (F2022L00455) | 1 Apr 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 4) (PB 34 of 2022) | 29 Apr 2022 (F2022L00643) | 1 May 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 5) (PB 44 of 2022) | 27 May 2022 (F2022L00725) | 1 June 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 6) (PB 55 of 2022) | 29 June 2022 (F2022L00870) | 1 July 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 7) (PB 68 of 2022) | 29 July 2022 (F2022L01024) | 1 Aug 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 8) (PB 79 of 2022) | 26 Aug 2022 (F2022L01110) | 1 Sept 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 9) (PB 86 of 2022) | 30 Sept 2022 (F2022L01304) | 1 Oct 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 10) (PB 112 of 2022) | 30 Nov 2022 (F2022L01545) | 1 Dec 2022 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2022 (No. 11) (PB 121 of 2022) | 23 Dec 2022 (F2022L01752) | 1 Jan 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 1) (PB 2 of 2023) | 31 Jan 2023 (F2023L00062) | 1 Feb 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 2) (PB 22 of 2023) | 31 Mar 2023 (F2023L00394) | 1 Apr 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 3) (PB 35 of 2023) | 28 Apr 2023 (F2023L00501) | 1 May 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 4) (PB 44 of 2023) | 31 May 2023 (F2023L00655) | 1 June 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 5) (PB 55 of 2023) | 30 June 2023 (F2023L00903) | 1 July 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 6) (PB 68 of 2023) | 31 July 2023 (F2023L01041) | 1 Aug 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 7) (PB 80 of 2023) | 31 Aug 2023 (F2023L01148) | 1 Sept 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 8) (PB 92 of 2023) | 29 Sept 2023 (F2023L01332) | 1 Oct 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 9) (PB 113 of 2023) | 30 Nov 2023 (F2023L01581) | 1 Dec 2023 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 10) (PB 129 of 2023) | 22 Dec 2023 (F2023L01748) | 1 Jan 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 1) (PB 2 of 2024) | 31 Jan 2024 (F2024L00120) | 1 Feb 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 2) (PB 16 of 2024) | 29 Feb 2024 (F2024L00238) | 1 Mar 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 3) (PB 27 of 2024) | 28 Mar 2024 (F2024L00423) | 1 Apr 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 4) (PB 40 of 2024) | 30 Apr 2024 (F2024L00499) | 1 May 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 5) (PB 53 of 2024) | 31 May 2024 (F2024L00604) | 1 June 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 6) (PB 69 of 2024) | 28 June 2024 (F2024L00826) | 1 July 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 7) (PB 77 of 2024) | 31 July 2024 (F2024L00947) | 1 Aug 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 8) (PB 86 of 2024) | 30 Aug 2024 (F2024L01096) | 1 Sept 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 9) (PB 96 of 2024) | 30 Sept 2024 (F2024L01238) | 1 Oct 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 10) (PB 112 of 2024) | 31 Oct 2024 (F2024L01390) | 1 Nov 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 11) (PB 125 of 2024) | 29 Nov 2024 (F2024L01529) | 1 Dec 2024 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 12) (PB 139 of 2024) | 24 Dec 2024 (F2024L01732) | 1 Jan 2025 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 1) (PB 2 of 2025) | 31 Jan 2025 (F2025L00063) | 1 Feb 2025 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 2) (PB 14 of 2025) | 28 Feb 2025 (F2025L00216) | 1 Mar 2025 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 3) (PB 25 of 2025) | 31 Mar 2025 (F2025L00455) | 1 Apr 2025 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 4) (PB 41 of 2025) | 30 Apr 2025 (F2025L00535) | 1 May 2025 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 5) (PB 56 of 2025) | 30 May 2025 (F2025L00623) | 1 June 2025 (s 2(1) item 1) | — |
| National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 6) (PB 75 of 2025) | 30 June 2025 (F2025L00776) | 1 July 2025 (s 2(1) item 1) | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| s 2 | rep LIA s 48D |
| s 3 | rep LIA s 48C |
| s 4 | rs F2023L01041 |
|  | am F2023L01581 |
| s 5 | rs F2023L01581 |
| s 6 | ed C26 |
|  | rs F2023L01581 |
| s 7 | rs F2023L01581 |
| s 8 | ad F2023L01581 |
| **Schedule 1** |  |
| Schedule 1 | am PB 4, 12, 21, 32, 54, 66, 75, 83, 92, 99 and 111 of 2016; PB 4 of 2017; PB 19 of 2017; PB 29 of 2017; PB 38 of 2017; PB 46 of 2017; PB 65 of 2017; PB 74 of 2017; PB 87 of 2017; PB 94 of 2017; PB 103 of 2017; PB 4 of 2018; PB 15 of 2018; PB 21 of 2018; PB 32 of 2018; PB 39 of 2018 |
|  | ed C26 |
|  | am PB 52 of 2018; PB 65 of 2018; PB 76 of 2018; PB 93 of 2018 |
|  | ed C30 |
|  | am PB 100 of 2018; PB 2 of 2019; PB 12 of 2019 |
|  | rs PB 19 of 2019 |
|  | am PB 30 of 2019; PB 38 of 2019; PB 47 of 2019; PB 60 of 2019; PB 68 of 2019; PB 77 of 2019; PB 86 of 2019; PB 94 of 2019; PB 105 of 2019; PB 3 of 2020; PB 15 of 2020; PB 21 of 2020; PB 34 of 2020; PB 56 of 2020; PB 68 of 2020; PB 79 of 2020; PB 90 of 2020; PB 103 of 2020; PB 112 of 2020; PB 125 of 2020; PB 2 of 2021; PB 14 of 2021; F2021L00395; F2021L00518; F2021L00655; F2021L00893; F2021L01054 |
|  | ed C61 |
|  | am F2021L01219; F2021L01358; F2021L01487; F2021L01651; F2021L01895; F2022L00090; F2022L00202; F2022L00455; F2022L00643; F2022L00725; F2022L00870; F2022L01024; F2022L01110; F2022L01304; F2022L01545; F2022L01752; F2023L00062; F2023L00394; F2023L00501; F2023L00655; F2023L00903; F2023L01041; F2023L01148; F2023L01332 |
|  | rs F2023L01581 |
|  | am F2023L01748; F2024L00120; F2024L00238; F2024L00423; F2024L00499; F2024L00604; F2024L00826 (Sch 1 item 9 md not incorp); F2024L00947; F2024L01096; F2024L01238; F2024L01390; F2024L01529; F2024L01732; F2025L00063; F2025L00216; F2025L00455; F2025L00535; F2025L00623; F2025L00776 |
| **Schedule 2** |  |
| Schedule 2 | ad F2023L01581 |
|  | am F2023L01748; F2024L00238; F2024L00499; F2024L00604; F2024L00826; F2024L01096; F2024L01390; F2024L01529; F2024L01732; F2025L00216; F2025L00455; F2025L00535; F2025L00623; F2025L00776 |